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IDENTIFICATION OF INTRACRANIAL LESIONS WITH DUAL-ENERGY COMPUTED
TOMOGRAPHY AND MAGNETIC RESONANCE PHASE IMAGING

Megan C. Jacobsen, B.A.
Advisory Professors: Dianna Cody, Ph.D. & Dawid Schellingerhout, M.D.
Abstract
On conventional Single-energy Computed Tomography (SECT), lesions with an
attenuation greater than 100 Hounsfield Units (HU) can be definitively diagnosed as
calcification. However, low-density calcifications and hemorrhage may have overlapping
attenuation ranges between 40 and 100 HU and, therefore, cannot be differentiated with SECT
alone. On T2*-weighted Gradient Recalled Echo (GRE) MRI, these lesions appear as “foci of
susceptibility” in which their signal is hypointense due to the magnetic susceptibility of the
lesions differing from that of the background tissue.
Dual-energy Computed Tomography (DECT) and Phase-Sensitive Magnetic
Resonance Imaging (PS-MRI) represent two new imaging paradigms which both have the
potential to more accurately identify intracranial calcification and hemorrhage. In DECT, x-ray
tomography is acquired at two tube voltages; because x-ray attenuation is energy- and
material-dependent, the data can be used to differentiate between materials that may have the
same signal level on SECT. PS-MRI utilizes the phase data from T2*-weighted MRI
acquisitions to determine how the local magnetic field varies across the image. By applying
post-processing algorithms such as Quantitative Susceptibility Mapping (QSM), the phase can
be used to calculate the magnetic susceptibility of a lesion. Since calcifications are diamagnetic
and hemorrhage paramagnetic, we can make inferences about a lesion’s composition from
these algorithms.
The objective of this dissertation work was to characterize brain lesions, discovered with
traditional imaging methods, as either hemorrhagic or calcific by using Dual-Energy Computed
v

Tomography (DECT) and Phase-Sensitive Magnetic Resonance Imaging (PS-MRI). To this
end, MRI-compatible phantoms featuring models of both calcific and hemorrhagic lesions were
developed and validated. This resulted in two phantoms with biologically similar lesion models
that were then used to test the feasibility of differentiating calcific and hemorrhagic lesions with
PS-MRI post-processing methods, in which QSM was able to accurately differentiate calcific
and hemorrhagic lesion models. Finally, we undertook a patient trial testing the feasibility of
identifying calcification and chronic hemorrhage in humans using both DECT and QSM in
which the two modalities had accuracies of 99.7% (327/328) and 99.4% (326/328),
respectively. The two modalities were concordant for 99.3% (148/149) lesions with SECT
attenuation under 100 HU.
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Chapter 1
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1.1

Introduction

Significance
Using Single-Energy Computed Tomography (SECT), both hemorrhagic and calcific

lesions are hyperintense relative to the background brain tissue, and the CT numbers of both
lesion types may overlap, depending on their composition and density. Lesions that have a CT
number of over 100 Hounsfield Units (HU) on SECT are definitively calcific (1, 2); however, in
the region of approximately 50 – 100 HU, the signal levels of hemorrhage and low-density
calcifications overlap, and differentiation based on the CT number becomes unreliable. On
conventional T2*-weighted Gradient Recalled Echo (GRE) Magnetic Resonance Imaging
(MRI), both calcific and hemorrhagic lesions appear as black signal voids in the image known
as foci of susceptibility, and the two material types are indistinguishable. GRE pulse sequences
are highly sensitive to these lesion types, and foci of susceptibility are a common incidental
finding on brain MRI.
The presence of prior hemorrhage in the brain is a contraindication for anticoagulant
therapies because they increase the risk of large brain bleeds. Additionally, certain disease
profiles lend themselves towards either calcification or hemorrhage. Therefore, developing
methods do distinguish calcific and hemorrhagic lesions allows for improved risk management
and differential diagnosis amongst patients.

1.2

Objectives and Hypothesis
The objective of this project is to characterize brain lesions, discovered with traditional

imaging methods, as either hemorrhagic or calcific by using Dual-Energy Computed
Tomography (DECT) and Phase-Sensitive Magnetic Resonance Imaging (PS-MRI). These
1

modalities may increase or improve the information available to the radiologist regarding
differential diagnosis and clinical management. Hemorrhagic lesions carry a risk of further
bleeds while calcifications are generally benign. The central hypothesis is that DECT and
PS-MRI can be used to accurately classify foci of susceptibility detected on
conventional MRI as either hemorrhage or calcification.

1.3

Specific Aims

To test the central hypothesis, we have developed the following three specific aims:
Specific Aim 1: Design and construct an MRI-compatible phantom with calcific and
hemorrhagic lesion models.
Subaim 1.1: Design and build an MRI-compatible phantom with varying densities of
calcium and iron.
Subaim 1.2: Validate the phantom materials with conventional SECT, conventional
MRI, DECT, and PS-MRI.
Subaim 1.3: Construct a final MRI-compatible phantom with calcific and hemorrhagic
lesion models within biological constraints.
Specific Aim 2: Optimize the imaging acquisition schema and post-processing methods to
maximize the specificity of calcification and hemorrhage classification.
Specific Aim 3: Conduct a human trial comparing the identification of intracranial calcification
and hemorrhage using DECT and PS-MRI in vivo.
Subaim 3.1: Compare the accuracy of DECT and PS-MRI for identification of known
intracranial calcifications (lesions measuring greater than or equal to 100 HU on SECT).
Subaim 3.2: Assess the concordance of DECT and PS-MRI for identification of
intracranial hemorrhage and calcification measuring less than 100 HU on SECT.

2

1.4

Dissertation Organization
This dissertation is organized in the following way: Chapter 2 provides background

information on hemorrhagic and calcific lesions, DECT, and PS-MRI techniques. Chapter 3
details Specific Aim 1 and presents the results of the MRI-compatible calcification and
hemorrhage phantom experiments. Chapter 4 addresses Specific Aim 2 and covers the
development of the pulse sequences and the mathematical models used to differentiate
calcification and hemorrhage. Chapter 5 covers Specific Aim 3 and the results of a clinical trial
comparing the use of DECT and PS-MRI in vivo. Lastly, Chapter 6 summarizes the dissertation
and future avenues for this work.
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Chapter 2

2

2.1

Background

Rationale

2.1.1 Intracranial Hemorrhage
Intracranial hemorrhage (ICH) is associated with a wide variety of etiologies, including—but not
limited to—brain tumors, aneurysms, arteriovenous malformations, and hypertension (3, 4). In
our patient population within a large, academic cancer hospital, we are particularly concerned
with hemorrhage within brain malignancies as well as cavernous malformations, a type of
venous malformation that is a common incidental finding on brain Magnetic Resonance
Imaging (MRI) (5-7). Both lesion types may lead to clinically significant intracranial bleeding.

Cavernous malformations, also known as cavernomas or cavernous angiomas, are mulberryshaped bundles of blood vessels that are often asymptomatic (8-11). Cavernomas are found in
0.4-0.8% of the general population, and most are found incidentally on MRI (7, 12, 13).
However, de novo development of cavernous malformations following cranial radiation therapy
has been well documented in the literature (14-18). Amongst long-term survivors of childhood
malignancy treated with cranial irradiation, the incidence of cavernoma is estimated to be
between 3.0% and 31.5% (17-22). While there is a wide reported range of the frequency of
cavernomas amongst cancer survivors, this may be caused by differences in the follow-up time
and imaging techniques used in the reported studies. Cavernomas also carry an inherent risk
of larger clinical bleeds of 0.7 – 6.5% per person-year in prospective studies (9-11, 13, 23, 24).
The results of these studies can be found in Table 2.1. A study by Salman et al found that the
5-year risk of mortality due to a cavernous malformation hemorrhaging was 4.5% (25).
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Table 2.1: Summary of hemorrhagic event risk in patients with cavernous malformation.
Authors & Year

Number of

Hemorrhage

Re-hemorrhage

Patients

Rate/Patient-Year

Rate/Patient-Year (%)

(%)
Moriarity et al., 1999 (13)

68

3.1

NA

Kondziolka et al., 1995 (10)

122

1.3

4.5

Zabramski et al., 1994 (9)

31

6.5

NA

Flemming et al., 2012 (23)

292

2.25

6.19

Salman et al., 2012 (25)

139

2.4 (5-year risk)

29.5 (5-year risk)

Labauge et al., 2001 (11)

33

4.3

NA

The appearance of ICH on MRI and CT changes over time. ICH evolves through the following
phases: hyperacute (< 12 hours since onset), acute (12 hours to 2 days), early subacute (2-7
days), late subacute (8 days to 1 month), and chronic (> 1 month) (26). Hyperacute
hemorrhage consists primarily of fluid with blood products, including hemoglobin, and has an
attenuation of 40 – 60 Hounsfield Units (HU) (3, 26). As the lesion progresses through the
acute and early subacute states, clotting begins, the hematocrit level rises, and globin and
fibrin form, causing increases in x-ray attenuation to between 60 and 80 HU (3, 26). In the early
subacute phase, the clot retracts and further increases in attenuation up to approximately 100
HU before cell lysis begins and the protein structures of the clot are broken down, causing the
attenuation to decrease through the late subacute stage until the lesion becomes chronic (3,
26).

While the CT appearance of hemorrhage depends primarily on the density of the clot and the
associated iron levels, the MR appearance depends on the pulse sequence used and the form
of hemoglobin—or its byproducts—present at the time of imaging (Table 2.2). In the subacute
phase, oxyhemoglobin dominates the MRI signal in the lesion; the signal in the acute phase is
due to deoxyhemoglobin (3, 26). Deoxyhemoglobin is metabolized to methemoglobin, which is
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present within the intracellular compartment in the early subacute phase and is transferred to
the extracellular space as cell lysis begins in the late subacute phase (3, 26). Finally, the
methemoglobin is metabolized, and the iron is stored in hemosiderin deposits surrounding the
rim of the lesion (3, 26).
Table 2.2: Single-Energy CT and conventional MRI image properties of intracranial
hemorrhage by stage.
CT
ICH Stage Attenuation
(HU)
Hyperacute 40 – 60

Acute 60 – 80
Early
80 – 100
Subacute
Decreasing
Late
0.7 – 1.5
Subacute
HU/day

Hemoglobin
Product

T1-weighted
MR

T2-weighted
MR

T2*-weighted
GRE MR

Isointense or
Oxyhemoglobin Slightly
hyperintense

Hyperintense

Hypointense
Rim

Deoxyhemoglobin

Isointense or
hypointense

Hypointense

Hypointense
Rim
Progressing
to Center

Intracellular
Methemoglobin

Hyperintense

Hypointense

Hypointense

Extracellular
Methemoglobin

Hyperintense

Hyperintense

Hypointense

Hyperintense
or Isointense
Isointense or
Chronic 25 – 35 HU Hemosiderin
Hypointense
Core with
Hypointense
Hypointense
Rim
Note: Table adapted from reference (26) with additional data from reference (3).
2.1.2 Intracranial Calcification
Intracranial calcifications are a common incidental—and often normal—finding on imaging
examinations of the brain (27). The most common forms include calcification of the pineal
gland, which affects up to 40% of the population by age 20 (27), the choroid plexus (28), and
dura mater (29). The incidence of these physiologic calcifications increases with patient age
(27). Other types of calcification are a symptom of metabolic disorders, congenital or acquired
infections, parasitic disease, and both benign and malignant brain tumors (30-35). Disorders of
the parathyroid are associated with calcifications of the basal ganglia, subcortical white matter,
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thalami, and cerebellum (33-35). Examples of congenital etiologies featuring intracranial
calcifications include neurofibromatosis type II and Sturge-Weber syndrome (36-38). Infections
such as Human Immunodeficiency Virus (39), tuberculosis (40, 41), and the parasitic disease
neurocysticercosis (42) are also commonly associated with multiple calcifications within the
brain parenchyma.

In the realm of cancer diagnosis and treatment, the presence of calcification is particularly
important for differentiating oligodendroglioma from other brain cancers or benign intracranial
lesions. Up to 90% of oligodendrogliomas contain calcium deposits, while the majority of other
brain malignancies, including glioblastoma multiforme, typically do not (31, 32, 43). Additionally,
calcifications are a long-term effect of past radiotherapy to the brain and can be caused by
certain chemotherapies (44). Unlike intracranial hemorrhage, calcifications within the brain
typically do not cause morbidity to the patient.

On conventional T1- and T2-weighted MRI, calcifications do not consistently provide the same
signal intensity relative to normal tissue (45). Dense calcifications have low water content,
which lowers the available MR signal (46); meanwhile, diffuse calcifications may shorten T1
and T2 due to water’s interaction with the porous surface of the calcium salts (47). On T2*weighted MRI, calcium is consistently hypointense but can mimic microbleeds or hemorrhages.
On CT, a signal measurement of over 100 HU is a definitive marker for calcification (2);
however, diffuse calcifications may have CT numbers less than 100 and may mimic
hemorrhagic lesions using conventional SECT.
2.1.3 Anticoagulant Use among Cancer Patients
The risk of venous thromboembolism is increased for patients with cancer over those in the
general population, even in ambulatory patients, with rates of 4.1 to 7.4% (48-52). Inpatient
treatment of cancer leads to further increases in the likelihood of morbidity or mortality due to
7

thromboembolism. Consequently, oncology patients are frequently prescribed prophylactic
anticoagulation to minimize the occurrence of deep vein thrombosis and pulmonary embolism
(53-55). While this lowers overall morbidity from complications of cancer and its treatment, care
must be taken to appropriately use prophylaxis because of the risk of inducing a hemorrhagic
stroke.

The risk of bleeding from cavernous angiomas while on anticoagulant therapy has not been
well defined. Recently, several investigators have attempted to determine the risk associated
with antithrombotic therapies in patients with cavernomas. In a cohort of 292 patients with
diagnosed cavernomas studied by Flemming et al, only six patients were placed on
anticoagulant therapy, and no prospective or recurrent bleeds were recorded amongst those
patients (56). Schneble et al also found that there were no hemorrhages in 26.4 person-years
of observation amongst five patients with diagnosed cavernoma that were prescribed warfarin
(57). However, there have been several documented case studies of cavernous angioma
bleeds occurring in patients receiving antithrombotic therapy, including one instance of a known
asymptomatic cavernoma hemorrhaging following treatment with low-molecular weight heparin
following surgery (58, 59). Overall, due to the small sample sizes in these studies, the results
cannot be considered conclusive (57, 60, 61).

Anticoagulant use is contraindicated in patients that have had prior bleeds within the brain
because the risk of large, symptomatic hemorrhage is increased following smaller bleeds that
may have been asymptomatic and found incidentally. These include all lesions that may have
indications of chronic or acute hemorrhage on imaging exams of the brain, including, but not
limited to venous malformations, primary brain tumors, and hemorrhagic metastases of the
brain.
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2.2

DECT Implementations and Image Reconstruction

Dual-Energy Computed Tomography (DECT) provides unique opportunities to differentiate
materials in the human body. The theoretical underpinnings of DECT were developed in the
late 1970s and first implemented in the 1980s (62-67). However, due to limitations in the CT
hardware and computing power, the potential of DECT was not fully realized until the first
commercial dual-source CT scanner was released in 2005 (68). As of 2018, the major
manufacturers have added DECT capabilities to at least one of their commercially available CT
systems, and have independently developed variations on the hardware used to acquire DECT
exams and the software used to analyze the data (69).

DECT is based upon the premise that the CT number, measured in Hounsfield Units (HU),
varies with x-ray energy (E) according to the following equation (70):
𝐶𝑇 𝑁𝑢𝑚𝑏𝑒𝑟 = 1000 ×

𝜇𝑥 (𝐸) − 𝜇𝑤𝑎𝑡𝑒𝑟 (𝐸)
𝜇𝑤𝑎𝑡𝑒𝑟 (𝐸)

Equation 2.1

where 𝜇𝑥 represents the linear attenuation coefficient of an unknown material x and 𝜇𝑤𝑎𝑡𝑒𝑟 is
the linear attenuation coefficient for water. The linear attenuation coefficient is a function of xray energy and depends on the material. For example, iodine—commonly used in clinical CT
contrast agents—has a very high attenuation coefficient at low x-ray energies due to the
prevalence of photoelectric interactions with high Z materials, and the attenuation decreases as
the energy decreases due to Compton scatter becoming the predominant interaction at higher
energies. For low Z materials such as water, the attenuation coefficient is much more stable
with x-ray energy. The difference in the shapes of these curves allows for the differentiation of
materials with the use of two or more energy spectra (Figure 2.1).
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Figure 2.1: Linear attenuation coefficients for water, cortical bone, and Omnipaque 350
(iodinated contrast agent) demonstrating differences in the material attenuation
properties across a range of diagnostic x-ray energies. In this example, cortical bone
could be described as a linear combination of water and Omnipaque.
2.2.1 DECT Hardware Implementation
There are six major hardware implementations of DECT currently available in the marketplace.
The first commercially available DECT was a dual-source (DS) system with two x-ray tube and
detector arrays, which allowed for scanning with two separate energies (Figure 2.1b). The first
system of this type became available in 2005 (Definition, Siemens Healthineers, Forchheim,
Germany), and there have been two additional dual-source scanners released as of 2018
(Definition Flash and Definition Force, Siemens). There are several advantages to this type of
system. First, the potential spectral separation is maximized because there are two separate xray spectra, and additional filtration can be placed on one or both tubes to separate the spectra
further (71, 72). Since its first release, there have been two additional scanner models released
using this hardware scheme—the Siemens Definition Flash and Definition Force scanners—
known as 2nd and 3rd generation DS-DECT. One downside of these systems is that there is a
temporal mismatch between projections at the low and high energy levels; additionally,
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scattered radiation from one x-ray tube and detector pair can enter the other detector array,
known as cross-scatter, and must be accounted for during the image reconstruction process.

The second DECT hardware implementation to be released commercially was the fast peak
kilovoltage (kVp) switching systems (Figure 2.2a) developed by General Electric Healthcare
(HD750 and Revolution CT, GE Healthcare, Waukesha, WI). On these systems, the generator
switches from 80 kVp to 140 kVp between alternating projections. This acquisition method
allows for acquisition of DECT data in which the two spectra have a nearly perfect temporal
agreement but limits the degree of spectral separation that is feasible because added filtration
is not possible and data is acquired continuously during the kVp-switching process (73, 74).

Figure 2.2: Schematics of DECT hardware implementations currently available, including
a) fast kVp-switching, b) dual-source, c) dual-layer detectors, and d) split-filter systems.
11

Dual-layered detector DECT systems, such as the Philips IQon (Philips Healthcare, Best, The
Netherlands), also utilize a single x-ray tube (Figure 2.2c). These systems operate at a single
kVp, and the resulting data is split into two spectra by using a detector with two sets of
electronics. The top layer of the detector preferentially absorbs low-energy photons, while highenergy photons penetrate the first layer and are absorbed in the bottom layer of the detector.
The resulting data can either be used to create low- and high-energy image sets and DECT
reconstructions or the data acquired by the two layers can be combined to reconstruct a
conventional SECT image (75-78). It is unclear how well this method separates the spectra
since a high-energy photon could be scattered in the first layer, depositing a portion of its
energy in each detector layer. However, these systems are advantageous for performing
comparisons of DECT and conventional SECT (75) since DECT data can be stored for every
exam for later processing as needed without burdening radiologists with additional image
series.

Split-filter systems operate in dual-energy mode with a single x-ray tube run at 120 kVp but
create two different energy spectra along the z-axis of the scanner via the addition of additional
filtration (Figure 2.2d) (79, 80). Half of the supplementary filter is gold—softening the x-ray
spectrum—and half is tin, which hardens the spectrum (81-84). This paradigm results in
relatively little spectral separation, which may be further degraded by the presence of crossscatter. The available technique parameters are limited to helical scans with a low pitch to
obtain adequate photon counts in each energy bin. Additionally, these filters may induce
artifacts in the images when the air outside the body is included within the region of helical over
ranging due to the interpolation required to combine the data from various times and locations
along the z-axis. The poor temporal matching between the high and low energy projections
may also limit the use of certain reconstruction algorithms, and the long scan times make this
dual-energy technique more susceptible to motion artifacts.
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There are also systems designed to incorporate slow kVp-switching to acquire DECT data.
These scanners acquire two consecutive rotations at the same z-location at two different
energies. This method is utilized by the Canon (formerly Toshiba) Acquilion One CT (Canon
Medical Systems, Otawara, Japan) (85). This scanner is capable of scanning whole organs in
one rotation, which minimizes the chances of motion artifacts between projections. However,
there is still a temporal mismatch between the high and low energy projections. Compared to
fast kVp-switching, there is the potential for better spectral separation, but there has been
relatively little research performed using this DECT methodology to date (86-91).

Finally, there are scanners which can perform DECT acquisitions by first acquiring a scan at
low energy followed by a scan at higher energy (69, 92). While this is a highly cost-effective
option and provides very good spectral separation, it is particularly sensitive to patient motion,
and cannot be used to assess iodine concentrations in tissue because of the timing differences
between the two scans.
2.2.2 DECT Software Implementations
DECT data is processed either through projection-based methods, which are performed on the
raw sinogram data prior to image reconstruction (93-96) or by image-based methods that first
reconstruct low- and high-energy images and subsequently calculate DECT properties (97, 98).

Projection-based methods require temporal co-registration of the low- and high-energy
datasets; the fast kVp-switching and dual-layer detector systems utilize this approach to DECT
reconstruction. In these algorithms, DECT data is derived using basis material decomposition,
which posits that any material can be modeled as a linear combination of the attenuation
coefficients of two predefined materials, the proof of which is shown here. X-ray attenuation
depends on two primary mechanisms in the diagnostic energy range: photoelectric effect and
13

Compton scattering, the fraction of scatter caused by each mechanism is defined as 𝑓𝑃𝐸 and 𝑓𝐶 ,
respectively. Both 𝑓𝑃𝐸 and 𝑓𝐶 depend on the x-ray energy, 𝐸. Therefore, the linear attenuation
coefficient (𝜇) of any material can be defined as a linear combination of the attenuation due to
each of those effects (Equation 2.2).
𝜇(𝐸) = 𝛼𝑓𝑃𝐸 (𝐸) + 𝛽𝑓𝐶 (𝐸)

Equation 2.2

Therefore, the attenuation of the basis materials 1 and 2 gives us the following system of
equations:
{

𝜇1 (𝐸) = 𝛼1 𝑓𝑃𝐸 (𝐸) + 𝛽1 𝑓𝐶 (𝐸)
𝜇1 (𝐸) = 𝛼2 𝑓𝑃𝐸 (𝐸) + 𝛽2 𝑓𝐶 (𝐸)

Equation 2.3

Solving Equation 2.3 for the photoelectric and Compton scatter fractions returns Equation 2.4
and Equation 2.5:
𝛽2 𝜇1 (𝐸) − 𝛽1 𝜇2 (𝐸)
𝛼1 𝛽2 − 𝛼2 𝛽1

Equation 2.4

𝛼2 𝜇1 (𝐸) − 𝛼1 𝜇2 (𝐸)
𝛼2 𝛽1 − 𝛼1 𝛽2

Equation 2.5

𝑓𝑃𝐸 (𝐸) =
𝑓𝐶 (𝐸) =

Equation 2.4 and Equation 2.5 define the photoelectric and Compton scatter fractions in terms
of the attenuation of materials 1 and 2. Substituting these back into Equation 2.2 returns:
𝜇(𝐸) = 𝛼 (

𝛽2 𝜇1 (𝐸) − 𝛽1 𝜇2 (𝐸)
𝛼2 𝜇1 (𝐸) − 𝛼1 𝜇2 (𝐸)
)+ 𝛽(
)
𝛼1 𝛽2 − 𝛼2 𝛽1
𝛼2 𝛽1 − 𝛼1 𝛽2

Equation 2.6

Equation 2.6 is algebraically equivalent to Equation 2.7.
𝜇(𝐸) = 𝑎1 𝜇1 (𝐸) + 𝑎2 𝜇2 (𝐸) where
𝑎1 =

𝛼𝛽2 − 𝛽𝛼2
𝛽𝛼1 − 𝛼𝛽1
and 𝑎2 =
𝛼1 𝛽2 − 𝛼2 𝛽1
𝛼1 𝛽2 − 𝛼2 𝛽1

Equation 2.7

The attenuation coefficients of materials 1 and 2 are known a priori. Measuring the attenuation
of the voxel in question at two energy levels returns a system of two equations with two
unknowns that can be solved to determine the amount of materials 1 and 2. The resulting
quantities of each material, which can be given in terms of density, represent the amounts of
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each material that would be required to model that voxel’s attenuation properties (Equation
2.8).
𝜇(𝐸𝑙𝑜𝑤 ) = 𝑎1 𝜇1 (𝐸𝑙𝑜𝑤 ) + 𝑎2 𝜇2 (𝐸𝑙𝑜𝑤 )
{
𝜇(𝐸ℎ𝑖𝑔ℎ ) = 𝑎1 𝜇1 (𝐸ℎ𝑖𝑔ℎ ) + 𝑎2 𝜇2 (𝐸ℎ𝑖𝑔ℎ )

Equation 2.8

It should be noted that while the basis materials can be chosen by the user, the two materials
selected must have sufficiently different attenuation properties in order to achieve an accurate
classification of materials. It is optimal to have one low Z material—water or soft tissue—and
one higher Z material—iodine or calcium. Additionally, users must be aware of the energy of
the K-edge of the material. Since CT data is polychromatic, the energy range over which data
is acquired is approximately 40 to 140 keV for a system with a maximum kVp of 140. As a
result, if the K-edge of the material of interest falls within this range, the attenuation differences
between the low- and high-energy measurements may not be large enough to calculate
accurate material density estimates (Figure 2.3).

Figure 2.3: Linear attenuation coefficients for gold (K-edge at 80.7 keV) and water. When
the K-edge falls between 40 and 140 keV, it is possible that the measured attenuation at
the low- and high-energies in DECT may return similar attenuation values.
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Image-space DECT analysis is performed following reconstruction of low- and high-energy CT
datasets (69, 99-101). All acquisition methods that cannot ensure temporal registration of the
two datasets use image-based reconstruction. These algorithms may use up to three materials,
which are mapped to predefined CT numbers in the low- and high-energy images and include a
volume conservation term where the sum of the volume fractions of each material must equal
one (96). Figure 2.4 shows a theoretical example of an abdominal virtual non-contrast
algorithm where the three materials are soft tissue, fat, and iodinated contrast. For a given
measured voxel, a, the point can be projected onto the line segment between the two lowdensity tissues to point b along a second line originating from the defined iodine point. Point b
represents the virtual non-contrast values for the voxel, and the distance between points a and
b, the length i, is proportional to the amount of iodine present in the voxel. The value i can be
presented as the attenuation in HU attributed to iodine enhancement or as an iodine
concentration. While this theoretical example utilized iodine as a high Z material, different
applications may utilize different materials than those depicted here.

Figure 2.4: Schematic of image-based three material decomposition. Point a represents
the CT numbers of a measured voxel at the low and high tube voltages. The measured
values are then projected onto the line between fat and soft tissue values along the red
16

line. Thus, point b represents the virtual unenhanced CT numbers while i represents the
amount of iodine present.

2.3

DECT Applications

2.3.1 Virtual Non-Contrast
One of the primary clinical applications of DECT is the digital removal of the signal caused by
the presence of iodine, known as Virtual Non-Contrast (VNC) or Virtual Unenhanced imaging
(68, 102-105). VNC enables clinics to perform a single contrast-enhanced scan of a patient and
produce a simulated non-contrast phase, which can help in efforts to lower patients’ exposure
to ionizing radiation and lower the costs associated with CT imaging. Vendors typically provide
a non-contrast or water image as well as an iodine map either in units of mg Iodine/mL
(General Electric, Philips) or the HU attributed to iodinated contrast (Siemens).

Many studies have been performed to assess the utility, image quality, and accuracy of virtual
non-contrast images (103, 106-108). The resulting iodine maps have been used to differentiate
between benign and malignant renal lesions (105, 109-112), identify metastatic disease in
lymph nodes (113-116), and improve visualization of pancreatic (117, 118) and gynecological
cancers (119). One common application of DECT virtual non-contrast imaging in neurology is
the differentiation of hemorrhage from residual iodinated contrast agent following mechanical
thrombectomy in patients with ischemic stroke (120-123).

Although these images may be useful clinically, there are disadvantages of which users must
be aware. When choosing materials for virtual non-contrast image processing, vendors use
iodine as the high-Z material in their processing algorithms and either one or two soft tissue-like
materials (water, soft tissue, fat, etc.). Materials must be classified as a linear combination of
these materials. Therefore, other high-Z materials such as calcium appear in both the virtual
non-contrast and the iodine map provided by the vendors.
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2.3.2 Virtual Monoenergetic Images
DECT data may also be used to create virtual monoenergetic images that simulate images
acquired with a monoenergetic x-ray source (67, 92, 124-126). Users can reconstruct images
at any energy between 40 keV and either 140 keV on GE systems or 190 keV on Siemens and
Philips systems. To create these images, the density of the low-Z material (soft tissue or water)
and iodine are calculated as detailed in section 2.2.2 for each voxel. Then, using the
attenuation coefficient of each material, as defined by the National Institutes of Standards and
Technology (NIST), is used in the following equation to estimate the total attenuation coefficient
at the user-defined energy.
𝜇
𝜇
𝜇𝑡𝑜𝑡𝑎𝑙 (𝐸) = ( ) (𝐸) ∙ 𝜌𝐿 + ( ) (𝐸) ∙ 𝜌𝐻
𝜌 𝐿
𝜌 𝐻

Equation 2.9

2.3.3 Calcium Identification
Since calcium is a high Z material with a low K-edge, calcium can be readily identified using
material decomposition, which is particularly useful because calcium and iodine can have very
similar attenuation levels using SECT. DECT, therefore, enables more accurate removal of
bony anatomy and removal of calcific plaques to improve visualization on CT angiography (84,
127, 128). Additionally, virtual calcium removal can lead to visualization of bone marrow edema
in fractures that may otherwise be difficult to diagnose without MRI (89, 129-132). Material
decompositions that incorporate calcium also enable quantitative estimates of calcium density,
which have been utilized to estimate bone mineral density (133, 134).
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2.3.4 Distinguishing Calcification and Hemorrhage

Figure 2.5: Attenuation curves for dense calcification (as modeled by low density cortical
bone) and whole blood products. Note that blood products have a very similar curve
shape as water with a slightly higher overall density.
There have been several studies published in the literature regarding the differentiation of
intracranial calcification from hemorrhage (135-138). First were two phantom studies by Nute et
al. demonstrating the feasibility of distinguishing these lesion types quantitatively using a
calcium and water material decomposition on a fast kVp-switching system (135, 136). Both of
these studies utilized an anthropomorphic head phantom and simulated calcific and
hemorrhagic lesions by doping agarose (135) and brain attenuation-equivalent epoxy-resin
(136) with calcium hydroxyapatite and iron oxide. Based on the attenuation curves for blood
products and bone, the authors found that by using a decomposition of calcium and water, a
plane of differentiation could be calculated that optimally separated the lesion types, as shown
in Figure 2.6 (136). Differentiation was possible primarily using the water(calcium) images, in
which hemorrhagic lesions would be iso- or hypo-intense, and calcific lesions would be
hyperdense (Figure 2.7). Using this method, they found that differentiation was possible at
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signal levels of 50 and 60 HU for 1.5cm and 1.0cm lesions in the cerebrum at 90% accuracy
(136).

Figure 2.6: Example of a plane of differentiation developed with geometric bisectors for a
1.5cm diameter lesion in the cerebrum, imaged at 132.5 mGy and reconstructed at 5 mm
image thickness with a soft filter. Voxel data for the hemorrhagic lesions are shown in
red, while voxel data for the calcific lesions are shown in gray.

Lesion differentiation was also tested on a dual-source DECT system in an emergency
department where all patients with suspected stroke underwent DECT imaging of the head
(137). They found that a 3-material decomposition using calcium, brain tissue, and hemorrhage
was capable of identifying calcific lesions because they were completely removed from the
virtual non-calcium images while the signal in hemorrhagic lesions was visualized in both the
calcium and soft tissue images. The authors confirmed the presence of hemorrhage on followup MRI and CT imaging (139). This technique, while not quantitative, had a sensitivity of 96%
and specificity of 100% for the detection of hemorrhage (137).

20

Figure 2.7: DECT reconstructions of a) 68 keV, b) calcium(water), and c) water(calcium) in
a phantom image acquired at 132.6 mGy CTDIvol with 5 mm slice thickness and a soft
reconstruction filter. Lesion models in the phantom were 80 HU at 120 kVp SECT. Solid
arrows indicate calcific lesions while unfilled arrows identify iron-based lesion models.

2.4

Magnetic Susceptibility

Magnetic susceptibility is an inherent property of any material represented by a dimensionless
scalar (χ). It represents the extent to which the material magnetizes when placed in a magnetic
field, and is equal to the magnetization of the object divided by the magnetic field strength.
Ferromagnetism is a unique property of certain compounds in which the material remains
magnetized after being removed from an external magnetic field caused by both the chemical
make-up of the material and a particular crystal structure. Ferromagnets are the magnetic
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materials most commonly encountered in daily life, but are not present naturally within the
human body; the forms of magnetism that are naturally occurring in humans are described
below.
2.4.1 Diamagnetism
Diamagnetic materials repel or weaken a magnetic field within a given material and have a
negative magnetic susceptibility. Water (χ = -9.035 x 10-6) and many tissues in the body are
slightly diamagnetic (140). The most common usage of the term diamagnetic in the medical
literature refers to materials with a susceptibility less than that of water, including calcium
deposits (140-144).
2.4.2 Paramagnetism
Paramagnetic materials are also common within the human body. These materials have a
positive susceptibility, so a magnetic field is locally strengthened in the material. For truly
paramagnetic materials, the amount of magnetism is directly proportional to the strength of the
applied field. Paramagnetism is caused by the spin of unpaired electrons within a material, and
in total only a small portion of the spins orient with the field, so the effect is weak. Examples of
materials that are paramagnetic relative to water are deoxyhemoglobin and iron deposits in the
form of ferritin and hemosiderin.
2.4.3 Superparamagnetism
Superparamagnetism occurs in materials where very small individual paramagnetic particles
each have an individual magnetic domain within a non-magnetic medium. These single domain
particles each have their own magnetic moment, and together the total moment, when exposed
to a magnetic field, is orders of magnitude higher than that of a typical paramagnet. The effect
is present because materials with larger particles tend to form grains of magnetic materials that
interact with each other and do not individually align with the applied magnetic field. One
example of this phenomenon is superparamagnetic iron oxide nanoparticles (diameter < 30
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nm), which have a much higher susceptibility for a given iron concentration than iron oxides
with larger particles (145).

2.5

MRI Phase Basics

The Magnetic Resonance Imaging (MRI) data required to form an image comes from the spin
precession of hydrogen nuclei, known as the Proton Resonance Frequency (PRF). To fully
describe the location of the precessing spins, the data is acquired in quadrature, meaning that
the signal acquired is acquired along two orthogonal directions (146, 147). The signal can be
modeled as a complex number, where one channel is labeled “real” and the other “imaginary”
(Figure 2.8).

Figure 2.8: Diagrammed relationship between the MRI signal (S), the components
measured in the real (Re) and imaginary (Im) channels, and the magnitude and phase of
the signal.
The signal can also be expressed in the rotating frame of reference in terms of its magnitude,
|𝑆|, and phase angle, 𝜑:
𝑆 = |𝑆|𝑒 𝑖𝜑

Equation 2.10

The exact magnitude of the signal depends on the magnetic field strength, the pulse sequence
used, and the following material properties: T1, T2, T2*, and proton density. The proton density
is proportional to the number of hydrogen atoms in the voxel of interest. T1 represents the rate
at which longitudinal magnetization is regained following excitation into the transverse plane by
an RF pulse. T2 is the rate at which the transverse magnetization dephases based on nuclear
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interactions only, whereas T2* is the observed relaxation rate when accounting for magnetic
field inhomogeneities, and T2’ is proportional to the change in the local magnetic field at the
inhomogeneity (Equation 2.11).
1
1
1
=
+
∗
𝑇2
𝑇2 𝑇2′

Equation 2.11

Phase is measured over the range of [-𝜋, 𝜋], so a true phase value of 2𝜋 would be mapped to a
measured phase of 0. This results in an effect called phase wrapping, in which sharp
boundaries in the phase image occur between a phase of -pi and +pi, as depicted in Figure 2.9.

Figure 2.9: The MRI phase image displayed depicts phase wrapping at boundaries
between -pi and pi. Additionally, noise is amplified in low signal regions of the image.
2.5.1 Gradient Recalled Echo Pulse Sequences
Gradient recalled echo (GRE) pulse sequences are used when the application requires fast
scanning or scanning of a large volume, including but not limited to perfusion, angiographic,
and cardiac imaging. Following the initial RF excitation pulse, the free induction decay signal is
rephased for readout using a gradient pulse. Spin echo sequences that utilize a 180° RF pulse
to refocus the signal also refocus off-resonance effects caused by local magnetic field
inhomogeneities (70, 146). GRE sequences cannot refocus these spins that are resonating off
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of the expected frequency, and so these cause artifacts in the images. As a result of these offresonance effects, GRE sequences are T2*-weighted rather than T2-weighted, and regions
with differences in susceptibility relative to the background are emphasized because they
change the local magnetic field. The echo time (TE), repetition time (TR), and flip angle (𝛼) of
the pulse sequence determines the exact weighting of the sequence, and the signal of a
spoiled GRE is also dependent on the T1 and T2* of a material, and is adjusted by a scaling
factor f:
𝑆(𝑇𝐸) = 𝑓

sin 𝛼 (1 − 𝑒 −𝑇𝑅/𝑇1 ) −𝑇𝐸/𝑇2∗
𝑒
(1 − cos 𝛼 ∙ 𝑒 −𝑇𝑅/𝑇1 )

Equation 2.12

Despite the number of factors that impact the image weighting, TE is the primary factor that will
influence the degree of T2* weighting in the final image, and lower TE images will feature
higher SNR and fewer susceptibility artifacts than those images with higher TE.

2.5.2 Magnetic Susceptibility and MRI Phase
As described in section 2.4, paramagnetic and diamagnetic materials increase and decrease
the magnetic field, respectively. The effective magnetic field (𝐵𝑒𝑓𝑓 ) is defined by the following
equation, where 𝐵0 is the strength of the main magnetic field, and ∆𝜒 is the difference in the
susceptibility compared to that of the background (148).
𝐵𝑒𝑓𝑓 = (1 + ∆𝜒)𝐵0

Equation 2.13

The effective magnetic field in the region with differing susceptibility causes the spins to
precess at a slightly different rate from the spins present in normal tissue. Therefore, at the TE
in a GRE sequence—in which these spins are not rephased by a 180° RF pulse—there is an
accumulation of phase in accordance to the following equation (148):
𝜑(𝑡) = −𝛾𝐵0 (𝑇𝐸 + ∆𝜒)

Equation 2.14

The true phase can, therefore, be used to estimate the susceptibility of a lesion. However,
there are confounding factors that must be accounted for to calculate the correct phase value
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for a given voxel. First, phase wraps (Section 2.5) must be eliminated by one of various phase
unwrapping algorithms, which becomes increasing challenging as the number of spatial
dimensions increases (149-151). Once phase wraps are successfully removed, the image is an
estimate of the magnetic field perturbation (152). Additionally, there are background phase
variations caused by non-local effects such as inhomogeneities in B0, large susceptibility
differences (for example, air-tissue interfaces), and eddy currents (153, 154). The simplest
method of removing the background phase is to use a high-pass filter to remove the low
frequency components of the image (155, 156). Other methods have estimated the background
phase using polynominal fitting (157-159), forward calculations using a priori knowledge of the
background susceptibility distribution (160), and models of magnetic dipole sources outside of
the region of interest (154) in attempts to model the phase more accurately.

2.6

Susceptibility-Weighted Imaging

Susceptibility-weighted imaging (SWI) is a technique for improving the visualization of veins
and other high-susceptibility tissues (Figure 2.10). The method utilizes a background
subtracted phase image to create an image mask, usually created by passing a high-pass filter
over the phase image (161). Following background phase removal, the phase mask is created
by scaling the phase using the following equation (162):
𝜋 + 𝜑(𝑥)
,
−𝜋 < 𝜑(𝑥) < 0
Equation 2.15
𝑓(𝑥) = {
𝜋
1,
otherwise
where 𝑥 specifies voxel location and 𝜑(𝑥) is the phase at that location. The magnitude image
𝜌(𝑥) is utilized to create the susceptibility-weighted image 𝜌̂(𝑥) according to the formula:
𝜌̂(𝑥) = 𝑓 𝑛 (𝑥) ∙ 𝜌(𝑥)

Equation 2.16

In which 𝑛 represents the number of times the phase mask is multiplied by itself, and is chosen
to change the susceptibility weighting and optimize the signal to noise ratio (SNR) (161, 163). It
has been shown that 𝑛 = 4 provides an optimal balance between enhancing the image contrast
of venous structures while maintaining SNR (164).
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Figure 2.10: Susceptibility-weighted imaging (SWI) improves visualization of venous
structures, as shown by comparison of a T2*-weighted GRE (a), Susceptibility-Weighted
Angiography (b). The high-pass filtered phase image (c) from the SWAN sequence
emphasizes the local magnetic field changes near the susceptibility lesion (black
arrows).
The typical scaling of SWI does not differentiate between negative and positive phase
accumulation. As a direct result, calcification and hemorrhage cannot be differentiated using
the phase scaling in Equation 2.15. Other phase masks have been developed, such as a
triangular mask that accounts for negative phase values (165); however, these are not
commonly applied in SWI applications provided by MR vendors.

2.7

Quantitative Susceptibility Mapping

Quantitative Susceptibility Mapping (QSM) is an MRI phase-based post processing technique
to reconstruct tomographic maps of magnetic susceptibility in tissue (148, 153, 162, 166).
Following phase unwrapping and background phase removal, QSM solves an inverse problem,
going from the measured magnetic field perturbation around a distribution of magnetic dipoles
back to the susceptibility distribution that caused it (148). Because GRE pulse sequences are
inherently sensitive to magnetic susceptibility, they are an obvious choice for QSM acquisitions.
All QSM post-processing is vulnerable to noise in the phase images. High noise in the phase
image is of particular concern in large hemorrhagic or calcific lesions where the signal is very
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low, and thus noise is amplified significantly (Figure 2.9). As a result, multi-echo GRE
sequences are most commonly used to acquire data for QSM processing because the phase
can be calculated more accurately by assessing the temporal evolution of the phase as the TE
changes, as shown in Figure 2.11 (152).

Figure 2.11: A multi-echo gradient recalled echo sequence (magnitude image, a) is used
to generate a background subtracted phase image (b) and a Quantitative Susceptibility
Map (c). Note the pineal calcification (arrow) and a punctate paramagnetic lesion in the
globus pallidus (arrowhead) that both appear hypointense in the magnitude image and
can be differentiated in the QSM.
2.7.1 Mathematical Derivation of the Inverse Problem
⃗ (𝑟), which is proportional to the distribution of the
A predefined magnetization distribution 𝑀
⃗ (𝑟 ), that is equal to
magnetic susceptibility, induces a magnetic field variation ∆𝐵

⃗ (𝑟 ) =
∆𝐵

⃗ (𝑟 ′ )(𝑟 − 𝑟 ′)2
⃗ (𝑟 ′ )
𝜇0
3𝑀
𝑀
∫{
−
} 𝑑 3 (𝑟 ′ )
|𝑟 − 𝑟 ′|5
|𝑟 − 𝑟 ′|3
4𝜋

Equation 2.17

𝑉

where 𝑟 represents coordinates in Cartesian space and 𝜇0 represents the magnetic
permeability in free space. We can assume that the main magnetic field resides solely in the z
direction, so Equation 2.17 simplifies to:
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∆𝐵𝑧 (𝑟 ) =

𝜇0
3𝑀𝑧 (𝑟 ′ )(𝑧 − 𝑧′)2
𝑀𝑧 (𝑟 ′ )
∫{
−
} 𝑑 3 (𝑟 ′ )
|𝑟 − 𝑟 ′|5
|𝑟 − 𝑟 ′|3
4𝜋

Equation 2.18

𝑉

where ∆𝐵𝑧 (𝑟 ) is the magnetic field variation along the z-axis. Equation 2.18 can be represented
⃗ (𝑟 ).
as a convolution of the magnetization distribution with the magnetic dipole kernel, 𝐷
∆𝐵𝑧 (𝑟 ) = 𝜇0 𝑀𝑧 (𝑟 ) ∗ 𝐷(𝑟 )
= 𝜇0 𝑀𝑧 (𝑟 ) ∗ [

1 3 cos2 𝜃 − 1
]
4𝜋
𝑟3

Equation 2.19

From this point, we assume that the susceptibility at any given point is sufficiently small to
assume that 𝑀𝑧 (𝑟 ) ≈ 𝐵0 𝜒(𝑟)/𝜇0. The problem is better posed in the frequency domain (kspace), so the Fourier transform is taken (𝐷(𝑘⃗) = 𝐹𝑇{𝐷(𝑟 )}), and the convolution theorem is
applied to Equation 2.19, returning the desired inverse problem, in which 𝑘⃗ represents a vector
in frequency space and 𝑘𝑧 is the z-component of the vector.
∆𝐵𝑧 (𝑘⃗) = 𝐵0 𝜒(𝑘⃗) × 𝐷(𝑘⃗ )

Equation 2.20

1 𝑘𝑧2
Equation 2.21
−
3 |𝑘⃗|2
Since ∆𝐵𝑧 (𝑟 ) is measured and the remaining quantities are known, the inverse problem can be
𝐷(𝑘⃗) =

solved to calculate the distribution of 𝜒(𝑟 ). However, in k-space, the dipole moment (Equation
2.21) is equal to zero along a cone at an angle of 54.7° (hence known as the “zero cone”), and
therefore the problem is ill-posed (152, 153, 167-169).
2.7.2 QSM Methods
Because solving for the susceptibility distribution is ill-posed, many methods have been
implemented to correct for the streak artifacts that would otherwise be induced by the zeros in
the dipole moment. The gold standard for accurately measuring the susceptibility is
“Calculation Of Susceptibility through Multiple Orientation Sampling,” or COSMOS (170-172).
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The COSMOS technique requires multiple acquisitions of GRE data with the sample in different
orientations to effectively average out the effect of the zero cone, ensuring that no point in kspace is filled with zeros. Thus, the inverse problem can be solved directly. This method is
highly accurate but time consuming and difficult for many body regions outside of the
extremities and the head.

Because of the logistical constraints of implementing COSMOS for QSM measurements in
vivo, multiple processing methods have been developed that utilize a single GRE acquisition to
estimate the susceptibility. What these methods have in common is that they utilize some form
of regularization. The first of these methods is Thresholded K-space Division (TKD), in which
very small or zero values in the dipole kernel are replaced with a constant (173-176). This
method reduces streaking artifacts caused by the zero cone, but it can induce artifacts
elsewhere in the image if phase shifts are not caused by susceptibility.

Several methods use iterative computational techniques to calculate a solution to the inverse
problem. The difference between the measured magnetic field and the convolution of the dipole
moment and calculated susceptibility distribution is computed first. The end goal is to minimize
the sum of the L2 norm of this difference and a regularized prior information term. The prior
information completes the missing data in k-space. Other similar techniques include using a
sparse linear equation and least squares (LSQR) approach (177, 178), piecewise constant
regularization (157), non-linear regularization of the susceptibility gradients (179, 180), and
methods requiring anatomical or morphological agreement (167, 181). Morphology-Enabled
Dipole Inversion (MEDI) is the most prominent QSM method using this scheme. The prior
information in MEDI is taken from the magnitude images, and edges in the magnitude image
are assumed to correspond with true edges in the calculated susceptibility map (167, 182,
183). Disadvantages of this technique include mismatches in the calculated susceptibility
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values where the anatomic edges and edges in the true susceptibility distribution do not match
(152).

A final group of algorithms only fills in ill-conditioned k-space data rather than using prior
information to inform the whole dataset. These methods split k-space into various subdomains,
and the ill-conditioned portions are reconstructed separately from the other domains. The
susceptibility distribution is optimized subject to either a sparse L1 norm or total variation norm
(152). The Homogeneity-Enabled Incremental Dipole Inversion (HEIDI) technique is one
particular example of this subdomain-based QSM method (184). These methods tend to be
quite accurate when compared to COSMOS and eliminate streak artifacts effectively (184).
2.7.3 QSM Applications
The primary sources of susceptibility in human tissues are iron, calcium, lipids, and myelin
(140, 185). While there has not been an investigation to date using QSM to quantify the fat
content of tissues since other methodologies, such as the Dixon method, have proven accurate
in this area, diseases that cause myelin degeneration, dysregulation of iron metabolism, and
diseases featuring calcifications have been studied using QSM.

Myelin sheaths cover the axons of nerves to insulate them from outside electrical currents. In
diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS),
demyelination of nerves in gray matter and the spinal cord is a clinical feature of the disease
(186, 187). Cancer treatment with cranial radiation is also a common cause of demyelination of
brain tissue, and has been shown to cause changes in normal-appearing white matter (188,
189). Myelin is diamagnetic compared to water due to its high phospholipid content, and so
susceptibility will increase as demyelination occurs. This increase in magnetic susceptibility has
been observed in several studies using QSM (190, 191).
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Iron-containing lesions, such as hemorrhage (see section 2.1.1) (192-194), cerebral
microbleeds (184, 195, 196), traumatic brain injury (196, 197), and chronic MS lesions (190,
191, 198, 199), have been the primary diagnostic targets of QSM to date. These lesions are
highly paramagnetic compared to water, so they have improved the ability of clinicians to
identify them and quantify disease progression. Deep gray matter also has very high iron
content, so QSM improves the anatomic visualization of tissues within the basal ganglia
(putamen, globus pallidus, and choroid plexus), thalamus, red nucleus, and dentate nucleus
(184, 192, 200-203).

Calcifications, often composed of hydroxyapatite (𝜒 = -14.83 ppm), are also prominent in
various diseases (see section 2.1.2) (140, 204). QSM provides differentiation of calcific and
hemorrhagic lesions in agreement with conventional SECT (45, 205, 206), and has improved
the visualization of calcifications compared to methods utilizing background corrected phase
images from T2*-weighted GRE (142) and susceptibility-weighted imaging sequences (207,
208). To date, the ability of QSM to identify calcifications below 100 HU on SECT has not been
studied.
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Chapter 3

3

3.1

Lesion Differentiation in Magnetic Resonance Imaging Phantoms

Introduction

The differentiation of intracranial calcifications and hemorrhage using imaging is of critical
importance to patient diagnosis and care. In particular, low density lesions that fall below 100
Hounsfield Units (HU) on conventional Single-Energy Computed Tomography (SECT) are of
interest to researchers because the signal level of hemorrhage and low-density calcifications
overlaps within this range. Multi-echo T2*-weighted GRE sequences are highly sensitive to
hemorrhage, but the characterization is challenging because calcifications also appear as black
spots due to their inherent magnetic susceptibility. Techniques that utilize the complex phase
data from a GRE acquisition, known as Phase-Sensitive Magnetic Resonance Imaging (PSMRI) methods, have been utilized in clinical research studies to differentiate calcific and
hemorrhagic lesions in vivo successfully. However, the in vivo studies currently available in the
literature relied on a SECT threshold to determine if a lesion was calcific, which is not an
adequate gold standard for low density lesions (45, 205, 206). To circumvent this issue, we
have developed multiple agarose-based phantoms to use as a gold standard comparison for in
vivo studies.

Multiple studies in the literature have examined the use of parametric MRI for identifying calcific
and hemorrhagic lesions on T2* maps. A study published in Radiology by Langkammer et al.
demonstrated that R2*-mapping (R2* = 1/T2*) had a high correlation with iron content in the
brains of human cadavers (209). They found that the iron concentration in gray matter tissues,
including the globus pallidus, putamen, caudate nucleus, and thalamus, ranged from 49 to 205
mg iron/kg of wet mass (209). These iron levels corresponded to T2* range of 13.8 to 33.3 ms
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in these iron-laden normal tissues. In another study, 52 patients experiencing symptoms of
Parkinson’s disease, brain iron—frequently elevated in these patients—was highly correlated
with T2* parametric maps, and the T2* ranged from approximately 15 ms to 35 ms (210).
Within cavernomas suspected of bleeds, the T2* was as low as approximately 7.7 ms (211).
Roy et al. found that calcified neurocysticercosis lesions had a median T2* of 14.6 ms for
lesions with a 120 kVp SECT attenuation of 142.10 HU (212).

Based on these literature values, we qualitatively and quantitatively verified that the phantom
materials generated the expected MR signal decay curves with minimal image artifacts and
finally constructed several MR phantoms with calcific and hemorrhagic lesion models within
biological constraints.

3.2

Methods

3.2.1 MRI Phantom Materials
Many materials have been used in the literature to simulate calcific and hemorrhagic lesions.
Based on the literature and prior experience making agarose-based phantoms (136), we chose
to model calcification and hemorrhage using the materials listed in Table 3.1.
Table 3.1: Phantom materials simulating calcific and hemorrhagic lesions
Calcification Models

Iron Models

Hydroxyapatite (136, 213)

Iron(III) Oxide (214)

Calcium Chloride (215)

Iron(II) Chloride (193)
Iron(III) Chloride (193, 211)
Iron Dextran (216, 217)
Hemoglobin (211)

The materials, with the exception of hemoglobin, were suspended in 1% weight/volume
agarose gel (#0710; Amresco, Solon, OH) within cylindrical, plastic 1.8ml cryovials ( #375418;
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Thermo Scientific, Waltham, MA ). The hydroxyapatite (#289396; Sigma-Aldrich, St. Louis,
MO) and iron(III) oxide (#529311; Sigma-Aldrich) required emulsification in 0.01% Triton X
(#112K09721; Sigma Aldrich) with a magnetic stir bar overnight. Following emulsification, the
agarose was added, and the vials were agitated manually to ensure the uniform distribution of
material (136). Hemoglobin was dissolved in sterile Lactated Ringer’s solution (#07-19-75-231;
Baxter, Deerfield, IL) to reach physiologic concentrations.

The phantom background material was comprised of LB Agar Miller (#1102830500; Millipore
Sigma, Darmstadt, Germany) at a concentration of 3.7% weight/volume. This material provides
physical strength, the flexibility to choose the orientation of the phantom relative to the main
magnetic field and is reasonably tissue equivalent due to its protein and sodium chloride
content.
3.2.2 MRI Phantom Design
There were several aspects of the MRI phantom design to be considered before construction of
the phantom. First, a plastic container with a low magnetic susceptibility was required. Second,
the vials had to be held parallel to each other within the background medium and be sufficiently
far from the edges of the phantom to minimize the effect of signal loss at the air-phantom
boundary. With these concerns in mind, two phantom designs were created.
Preliminary Phantom Design
The preliminary phantom design utilized a 12 cm x 12 cm test tube rack made of polypropylene
for gel placement. Holes were drilled in the bottom of the test tube rack to enable removal of
the vials. The tops of thirteen vials were wrapped in Parafilm M (P 7793; Sigma Aldrich, St.
Louis, MO) and inserted into the test tube rack (Figure 3.1a). The agarose background was
prepared and poured into a heat-safe polypropylene storage container with dimensions of 15.6
cm x 15.6 cm x 8.6 cm (Ziploc Medium Square Container, SC Johnson, Racine, WI) and
allowed to cool to a temperature of 50°C. The test tube rack was then inverted and placed in
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the container so that the vials were immersed in the agarose. The phantom was then stored at
4°C overnight to allow the agarose to set, and the test tube rack was removed, using a
toothpick to release the vials from the test tube rack. Phantoms utilizing this design had
abbreviations beginning with “P” to indicate the use of the preliminary design.

Figure 3.1: Preliminary phantom design demonstrating the vial positioning in the test tube
holder (a) and the completed preliminary phantom (b) with the agarose background.
Round Phantom Design
The preliminary phantom design allowed for a maximum of twelve samples and one control.
Additionally, using an existing test tube holder did not allow for even spacing of the vials within
the phantom or the ability to position all vials away from the phantom edge. Therefore, a
second design was conceived to alleviate these problems.

A 16-cm diameter, round, heat safe, polypropylene container (Large Bowl Food Storage
Container, H-E-B, San Antonio, TX) was chosen for the phantom. The phantom was designed
with a 2-cm buffer between individual samples. There was also greater than 2 cm between the
outer ring of vials and the phantom edge to minimize signal loss from the air-phantom
boundary. A total of nineteen samples fit within the container. A schematic of the phantom
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design is shown in Figure 3.2. A custom test-phantom template to hold the vials in place was
made from 1/8” craft plywood (Michaels, Irving, TX). Phantoms with this design were
abbreviated “R” for round phantom.

Figure 3.2: Schematic of the round phantom design. The cryovials measure 1 cm in
diameter, and all vials were greater than 2 cm from the edge of the phantom and 2 cm
away from all other vials.
3.2.3 Material Validation Phantoms
Hydroxyapatite and Iron (III) Oxide (P1 & P2)
Several phantoms were made to validate the materials used in each phantom. The
preliminary phantom design was used to create two phantoms that each contained six
hydroxyapatite vials and six iron(III) oxide vials. The goal of these phantoms was to test calcific
and hemorrhagic lesion models that had the same SECT HU value, as calculated using the
equations presented in Nute et al. (135). Low HU samples were grouped in one phantom
(Figure 3.3a) while high HU samples were placed in the second phantom (Figure 3.3b). The
material concentrations for the desired SECT HU are shown in Table 3.2.
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Figure 3.3: Iron oxide and hydroxyapatite phantoms a) P1, with low concentrations, and
b) P2 with high concentrations of the two materials. The concentrations displayed here
are in mg of analyte per mL.

Table 3.2: Hydroxyapatite and Iron(III) Oxide sample specifications for both low and high
concentrations.
Phantom

Low
Concentration
Phantom (P1)

High
Concentration
Phantom (P2)

Predicted
SECT (HU)
1
5
10
15
20
35
40
60
70
80
100
110

Iron(III) Oxide
Concentration
(mg/mL)
1.29
2.24
3.45
4.55
5.76
10.47
12.75
17.49
19.80
22.20
24.43
26.82

Hydroxyapatite
Concentration
(mg/mL)
4.35
6.94
10.12
13.37
16.59
23.02
29.37
42.27
48.71
55.10
67.96
74.39
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Hydroxyapatite and Iron Dextran (R1 & R2)
A hydroxyapatite and iron dextran (INFeD; Allergan, Dublin, Ireland) phantom was made with
the round phantom design, containing nine hydroxyapatite gels, nine iron dextran gels, and a
vial of Milli-Q water (Millipore Sigma). A 2-mL vial of iron dextran (50 mg iron/mL) was scanned
in air using SECT (HD750 CT; General Electric Healthcare, Waukesha, WI) to estimate the HU
before making the dilutions. The concentrations of each material used in the phantom are given
in Table 3.3. The SECT signal was approximately matched between the iron dextran and
hydroxyapatite gels to test the feasibility of using the same concentrations of iron dextran for
both CT and MRI lesion modeling. A schematic of the phantom is shown in Figure 3.4.
Table 3.3: Hydroxyapatite and Iron Dextran gel specifications and their estimated SECT
attenuation in HU for the first iron dextran testing. This phantom had approximately
matched SECT HU between the iron dextran and hydroxyapatite gels.
Phantom

ApproximatelyMatched SECT
HU (R1)

Iron Dextran
Concentration
(mg iron/mL)
0.59
1.77
3.54
5.89
8.25
10.61
11.79
14.15
32.41

Iron Dextran
Estimated SECT
HU
5
15
30
50
70
90
100
120
255

Hydroxyapatite
Concentration
(mg/mL)
13.22
24.82
42.24
48.00
59.53
74.16
117.61
146.51
194.24

Hydroxyapatite
Estimated SECT
HU
20
40
70
80
100
125
200
250
350
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Figure 3.4: Diagram of the phantom R1. Hydroxyapatite is shown in blue, iron dextran in
red, and 1% w/v agarose in gold. The numbers refer to the concentration of material in
each vial (iron dextran in units of mg Fe/mL, hydroxyapatite in mg/mL).
Following the scanning of phantom R1, another hydroxyapatite and iron dextran phantom (R2)
was developed which limited the iron concentration to avoid inducing chemical shift artifact
(Table 3.4, Figure 3.5). As a result, the SECT attenuation was not matched between the calcific
and hemorrhagic lesion models in phantom R2.
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Table 3.4: Hydroxyapatite and Iron Dextran gel specifications for a second phantom. In
this instance, SECT HU was not matched between the calcium and iron gels.
Phantom

Limited Iron
Concentrations
(R2)

Iron Dextran
Concentration
(mg iron/mL)
0.4
0.8
1.2
1.6
2
2.4
2.8
3.2
3.6

Hydroxyapatite
Concentration
(mg/mL)
7.8
15.7
23.5
31.4
39.2
58.8
78.4
137.3
196.1

Figure 3.5: Phantom R2 with adjusted iron dextran and hydroxyapatite concentrations.
Iron dextran concentration values in the diagram are given in mg Fe/mL while
hydroxyapatite concentrations are given in mg/mL.
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Hydroxyapatite and Calcium Chloride (R3)
Having a calcific substance that is soluble in water would improve the uniformity of the phantom
materials and potentially enable the use of higher concentrations of calcium to model materials
with more negative magnetic susceptibilities. A potential material was determined to be calcium
chloride, which had been used to make alginate gel beads in another MRI phantom experiment
(215). Serial dilutions of calcium chloride (CaCl 2) in 1% w/v agarose (2.0, 1.0, 0.5, 0.25, 0.1,
and 0.05 M) were prepared along with nine hydroxyapatite gels (13.2, 24.8, 42.2, 48.0, 59.5,
74.2, 117.6, 146.5, and 194.2 mg/mL) and two iron dextran gels (1.77 and 5.89 mg iron/mL) for
reference. This phantom will be abbreviated as R3.

Iron(II) Chloride and Iron(III) Chloride (R4)
The magnetic susceptibility of a compound depends primarily on the number of unpaired
electrons present in the molecule (140, 204). While oxyhemoglobin has no unpaired electrons,
deoxyhemoglobin has four unpaired electrons, and methemoglobin has five (204). The heme
iron must be in the 2+ state to bind oxygen, at which point it is oxidized to the 3+ state (218,
219). The goal of this phantom was to determine whether it was necessary to account for the
iron valence state to model the hemorrhagic lesions seen clinically. A 10 mg iron/mL stock
solution of FeCl2 (#50-901-14656; Fisher Scientific, Waltham, MA) was prepared in a 1% Lascorbic acid (#255564, Sigma Aldrich) buffer to ensure the iron remained in the 2+ valence
state. The FeCl3 stock was also prepared to a concentration of 10 mg iron/mL in MilliQ water.
1% agarose was added to dilute the solutions to the following concentrations: 0.0, 0.2, 0.4, 0.6,
0.8, 1.0, 1.2, 1.4, and 1.6 mg iron/mL. The vials were then arranged according to the round
phantom design
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Figure 3.6: Phantom R4 arrangement of iron(III) and iron(II) chloride samples. Units are
given in mg Fe/mL.
Biological Calibration Phantom (RF1)

Figure 3.7: Phantom RF1, a calibration phantom, featuring hydroxyapatite, iron dextran,
hemoglobin, and iron(III) chloride. The numbers above the vials refer to the concentration
in units of mg/mL for hydroxyapatite and mg Fe/mL otherwise.
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The goal of this phantom was to provide calibration curves over a biological range of T2*
values for calcifications and several iron-based compounds. Four vials each of hydroxyapatite,
iron dextran, iron(III) chloride, and hemoglobin (in Lactated Ringer’s solution) were made to the
specifications listed in Table 3.5. The vials were placed in the phantom as depicted in Figure
3.7. The phantom abbreviation used was RF1 to indicate that it was one of the round finalized
phantoms to be used in a future analysis (see Chapter 4).
Table 3.5: Specifications for concentrations of hydroxyapatite, iron dextran, iron(III)
chloride, and hemoglobin to be included in finalized calibration curves. Iron dextran
concentration is given in mg iron/mL due to the lack of a nominal density for the dextran
complex as a whole. Hemoglobin was assumed to be 0.31% iron per sample
specifications.
Hydroxyapatite
(mg/mL)
181.8
210.3
238.7
267.4

Iron Dextran
(mg Fe/mL)
0.70
1.40
2.10
2.80

Iron(III) Chloride
(mg Fe/mL)
0.31
0.62
0.94
1.25

Hemoglobin
(mg Fe/mL)
0.17
0.34
0.42
0.66

This phantom was scanned three times to test the repeatability of the MR results.
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Biological Phantom with Mixed Materials (RF2)

Figure 3.8: Diagram of the biological phantom with mixed materials. Lesion models with
diagonal stripes represent mixtures while vials with smaller spots represent regions of
differing material and concentration within a uniform background.
A final phantom (RF2) with a variety of mixed lesions was created to assess the feasibility of
identifying both mixtures of materials and smaller regions of differing susceptibility within a
larger lesion. In total, eight mixtures were made with iron dextran and one other material—
hydroxyapatite, iron(III) chloride, or lyophilized human hemoglobin—evenly distributed
throughout a 2% agarose background (Table 3.6). Eight additional lesion models were created
with simulated regions of a different material or material concentration, hence referred to as
“masses.” To manufacture the vials containing masses, several vials of hydroxyapatite and iron
dextran (concentrations found in Table 3.6) were created with a 5% w/v agarose background to
ensure structural integrity. Then a 5-mm Miltex standard biopsy punch (#3334; Integra
LifeSciences, Plainsboro, NJ) was used to remove a cylindrical piece of the gel approximately
3/8” deep. Agarose with the chosen background material was prepared at a concentration of
2% w/v and the cylindrical mass was gently inserted into the vial with a metal spatula before
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the agarose was set. A schematic of the vial placement within the phantom is provided in
Figure 3.8. This phantom was scanned three times to test the repeatability of the MR results.
Table 3.6: Agarose gel composition for a biological phantom with mixed materials. For the
lesions with masses (“Mass”), Material 1 indicates the composition of the uniform
background material while Material 2 indicates the concentration within the mass.
Concentrations are reported in mg Fe/mL for iron containing compounds and mg/mL for
hydroxyapatite
Label

Type

Material 1

HAP/ID 1
HAP/ID 2
HAP/ID 3
IC/ID 1
IC/ID 2
IC/ID 3
Hb/ID 1
Hb/ID 2
ID/HAPm 1
ID/HAPm 2
ID/HAPm 3
ID/HAPm 4
IC/IDm
ID/IDm 1
ID/IDm 2
ID/IDm 3

Mixture
Mixture
Mixture
Mixture
Mixture
Mixture
Mixture
Mixture
Mass
Mass
Mass
Mass
Mass
Mass
Mass
Mass

Hydroxyapatite
Hydroxyapatite
Hydroxyapatite
Iron(III) Chloride
Iron(III) Chloride
Iron(III) Chloride
Hemoglobin
Hemoglobin
Iron Dextran
Iron Dextran
Iron Dextran
Iron Dextran
Iron(III) Chloride
Iron Dextran
Iron Dextran
Iron Dextran

Material 1
Concentration
(mg Fe/mL
OR mg/mL)
210.2
210.2
210.2
0.47
0.31
0.16
0.34
0.17
0.70
0.70
2.10
2.10
0.31
1.40
0.70
0.70

Material 2

Iron Dextran
Iron Dextran
Iron Dextran
Iron Dextran
Iron Dextran
Iron Dextran
Iron Dextran
Iron Dextran
Hydroxyapatite
Hydroxyapatite
Hydroxyapatite
Hydroxyapatite
Iron Dextran
Iron Dextran
Iron Dextran
Iron Dextran

Material 2
Concentration
(mg Fe/mL
OR mg/mL)
2.10
1.40
0.70
0.35
0.70
1.05
0.70
1.05
267.1
181.6
267.1
181.6
0.70
0.70
1.40
2.80

3.2.4 MRI Scan Protocol
All phantom imaging was performed on a 3.0-T MRI system (MR 750, General Electric
Healthcare) with an 8-channel head coil. The phantom was positioned with the vials parallel to
B0 to minimize blooming. A three-dimensional (3D) T1-weighted ultrafast gradient echo with
magnetization preparation (IR-FSPGR) was acquired to assess geometric accuracy near the
vials. A T2*-weighted GRE was acquired for comparison of the signal level in the phantom to
conventional clinical images. 3D susceptibility-weighted angiography (SWAN) sequence was
acquired to examine the background phase—which is automatically reconstructed—in each
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material (see Chapter 4). Finally, a 3D multi-echo fast gradient recalled echo (MFGRE) was
acquired to assess signal changes with increasing echo time (TE) and calculate T2*, an
inherent property of a material indicating the time required for signal dephasing caused by
magnetic field inhomogeneity (for example, those caused by magnetic susceptibility) to occur.
Protocol details are shown in Table 3.7.
Table 3.7: MRI acquisition details for all phantom experiments, including repetition time
(TR), inversion time (TI), receive bandwidth (BW), field-of-view (FOV), acquisition matrix
Sequence

IR-FSPGR

T2*-weighted GRE

3D SWAN

3D MFGRE

# of Echo Times

1

1

6

12

TE (ms) [min, max]
2.1
15
23.3a
[4.7, 61.4]
TR (ms)
5.7
600
37.6
65.2
TI (ms)
400
Flip Angle
20°
20°
15°
20°
BW (kHz)
128
128
128
128
FOV (mm)
220
220
220
220
Phase FOV (% of FOV)
80
75
80
80
Matrix
256 x 256
256 x 256
320 x 224
416 x 320
Slice Thickness (mm)
1.4
5
1.4
1.4
Scan Time
4:27
2:00
2:49
6:46
a
SWAN provides images that are a weighted average of the six echoes. The average TE is
listed here.
SECT was also acquired to determine the conventional CT attenuation level of the vials within
the phantom and to ensure gel uniformity. All scanning was performed with our institution’s
routine brain protocol. DECT was also acquired for phantoms with matched SECT HU
(Hydroxyapatite and Iron Oxide phantoms and the first Hydroxyapatite and Iron Dextran
phantom). Both protocols are listed in Table 3.8. The phantoms were placed in the head holder
with the vials parallel to the z-axis of the scanner.
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Table 3.8: Phantom experiment SECT and DECT protocols.
Technique Parameter

SECT

DECT

Scan Type

Helical

Helical (GSI-9)

kVp

120

80/140

mA

220

600

Rotation Time (s)

0.8s

0.9

Pitch

0.531

0.531

CTDIvol (mGy)

65.2

132.6

Image Thickness (mm)

0.625

0.625

Interval (mm)

0.625

0.625

20

20

Head

Head

250

250

Beam Width (mm)
Scan FOV
Display FOV (mm)

3.2.5 Image Analysis
In phantoms P1-2 and R1-4, circular regions of interest (ROIs) approximately 7.5 mm in
diameter were placed within each vial on five consecutive images for the SECT, DECT (when
acquired) calcium(water) and water(calcium), and each echo of the MFGRE. The mean of the
voxels within each ROI was calculated; the standard deviation of the mean values (n = 5) was
used to measure the dispersion across the five images. For phantom RF1, the calibration
phantom, the mean and standard deviation of the signal over three acquisitions of the MFGRE
were calculated. The T2* GRE was assessed qualitatively for signal suggestive of susceptibility
lesions, where the signal decreases with increasing TE.

For a multi-echo T2*-weighted GRE pulse sequence, the signal in a uniform material is
expected to decay exponentially according to the following equation,
𝑆(𝑡) = 𝑆(𝑡 = 0) ∗ 𝑒 −𝑇𝐸/𝑇2

∗

Equation 3.1
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where 𝑆(𝑡) represents the signal at time 𝑡. The mean MFGRE signal in each vial was fit to this
equation using a non-linear least square fit in Matlab (R2016a; MathWorks, Natick, MA) to
calculate the T2*.

In phantom RF1, we tested reproducibility of the T2* calculations by performing the same
analysis found above across three acquisitions of the MFGRE. We calculated the mean T2*
and the standard deviation of the mean over the three acquisitions. In phantom RF2, voxelwise T2* calculations were made within the lesion models for one circular ROI (6.6 mm
diameter, 34.2 mm2 area) placed by hand within the lesion models. When a given lesion
contained a mass visible on the MRI, the ROI was placed at the z-location of the mass and
included both the mass and a portion of the background material to mimic the placement of an
ROI on a biological lesion with a mixed signal. The mean signal from each lesion was fit with
both a monoexponential curve (Equation 3.1) and a biexponential curve (Equation 3.2) to
characterize multiple materials within a single lesion model.
𝑆(𝑡) = 𝑎 ∗ 𝑒

𝑇𝐸
− ∗
𝑇2 1

+𝑏∗𝑒

𝑇𝐸
− ∗
𝑇2 2

Equation 3.2

The mean and standard deviation were calculated for each ROI on the T2* image. For lesions
with masses that visibly contained regions of differing T2* values, a histogram was generated,
and a kernel density estimator was applied in Matlab. The mean of each region was
determined by finding the locations of the peaks in the kernel density estimate. The peak
locations along the T2* axis of the histogram were compared to the values 𝑇2∗1 and 𝑇2∗ 2 from
the biexponential fit of the mean signal in the ROI.

3.3

Results

3.3.1 Hydroxyapatite and Iron Oxide Preliminary Phantoms
DECT water(calcium) and calcium(water) images were analyzed in both the low and high
concentration phantoms. As the concentration of each material increased, the mean measured
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calcium density increased for both materials (Figure 3.9), while the mean water value
decreased for iron-based lesion models and increased for calcific lesion models. This result is
in agreement with Nute et al. (135).

Figure 3.9: DECT water/calcium decomposition measurements for iron oxide and
hydroxyapatite samples with matched SECT HU. Calcium density increases as SECT HU
increases for both materials. Note that the use of the calcium/water material
decomposition does not indicate that calcium was present within the iron oxide samples
(see Section 2.3.4).

Figure 3.10: MFGRE magnitude images of the low concentration iron oxide (two bottom
rows) and hydroxyapatite (two top rows) phantom for echo times of a) 4.5 ms, b) 14.5 ms,
and c) 24.6 ms. At the highest echo time, the 10.47 mg/mL iron oxide sample (white arrow)
becomes distorted. Note that very little signal is present in the iron oxide samples, even
at low TE. Numeric labels represent the concentration of hydroxyapatite or iron oxide in
units of mg/mL.
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Low Concentration Phantom (P1)
The iron oxide demonstrated very low signals on the MFGRE pulse sequence, even at low
concentrations. The effect is demonstrated in Figure 3.10, where the six iron oxide mixtures are
shown in the bottom two rows of the phantom for echoes 1, 3 and 5 (TEs of 4.5, 14.5, and 24.6
ms). In Figure 3.10c, the shape of the vial containing the highest iron oxide concentration
(10.47 mg/mL) is warped into that of a magnetic dipole (white arrow). At the same TEs, the
hydroxyapatite vials show a slight decrease in the signal as echo time increases. In echoes 1
and 3, there is almost no difference in the signal that can be visually appreciated between
hydroxyapatite gels of different concentrations; by the fifth echo (Figure 3.10c), there begins to
be visually lower signal in those vials with higher concentrations of hydroxyapatite.

The quantitative analysis of the MFGRE signal showed that by a TE of approximately 30 ms,
virtually all signal had dephased in the iron oxide samples. Three vials (4.55, 5.76, and 10.47
mg/mL) had signal levels below 1000 AU at TE = 4.5 ms (Figure 3.11). The signal in each
sample was normalized to the first echo to improve visualization of the concentration
dependence, which can be noted for the three lowest concentration samples. T2* values were
calculated for each vial (Table 3.9), but due to the extremely low signal values in three of the
samples, the R2 of the exponential fit used to calculate the T2* was less than 0.2 and the
values are therefore considered to be inaccurate. In general, we would expect the T2* to
decrease with increasing iron presence in lesions with signal present above the noise floor.

The hydroxyapatite samples did not decay to the noise floor and had a much higher initial
signal than the iron oxide (Figure 3.12). For both materials, signal decayed steadily with
increasing TE, and normalizing the signal demonstrates a concentration dependence in the
decay rate. The T2* generally decreases with increasing analyte concentration (Table 3.9). The
vials containing the three lowest concentrations of hydroxyapatite were positioned near the
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edge of the phantom and were subject to increased signal decay due to proximity to the airphantom border, which may have impacted the T2* calculations.

Figure 3.11: Iron oxide MFGRE signal at low concentrations. The signal in all samples
dephased within a TE of 30 ms. Lower concentrations featured higher signal levels at
lower TEs. The signal normalized to the first echo for each vial shows very little change
in signal across the later echoes. The high normalized signal in the 10.47 mg/mL is solely
indicative of the very low signal values across all echoes.

Figure 3.12: Hydroxyapatite MFGRE signals for low concentrations. The signal decreased
steadily with increasing echo time (TE), and higher concentrations generally had lower
signal levels. The normalized signal shows that higher concentrations decay at a slightly
faster rate with increasing TE than lower concentrations.
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Table 3.9: T2* values for hydroxyapatite and iron oxide samples of varying concentrations.
The mean signal over five images was used to calculate T2*.
Hydroxyapatite
Calculated T2* (ms) Iron Oxide
Calculated T2* (ms)
Concentration
Concentration
(mg/mL)
(mg/mL)
4.35
71.38
1.29
8.29
6.94
63.50
2.24
4.54
10.12
57.60
3.45
3.60
13.37
71.39
4.55
**
16.59
63.15
5.76
**
23.02
48.90
10.47
**
**Curves were poorly fit by the monoexponential decay model, due to signal levels at the
noise floor for all TEs.
High Concentration Phantom (P1)
A qualitative analysis of the MFGRE images for the high concentration phantom shows little to
no signal in the iron-containing lesion models. However, there is a concentration dependence
to the apparent size of the sample at a given TE. This effect is exaggerated as the TE is
increased (Figure 3.13). The hydroxyapatite samples have similar signals regardless of
concentration at low TE (Figure 3.13a), and the concentration dependence of the signal level
becomes more obvious as TE increases (Figure 3.13c). There is no blooming artifact present in
the vials containing hydroxyapatite.

Figure 3.13: MFGRE magnitude images of the high concentration iron oxide (two upper
rows) and hydroxyapatite (two lower rows) phantom with a) TE = 4.5 ms, b) TE = 14.5 ms,
and c) TE = 24.6 ms. Numeric labels refer to the concentration of hydroxyapatite and iron
oxide in each sample in units of mg/mL. Note the blooming in the iron oxide samples
increases with TE and with increasing iron concentration.
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Quantitative analysis of the MFGRE signal with TE shows that the hydroxyapatite samples in
this phantom have a faster decay rate (lower T2*) than in the previous, lower concentration
phantom, which is depicted graphically in the normalized signal plot of Figure 3.14. The
concentration dependence of the signal decay is shown definitively in this phantom. The T2*
parameter calculated in these hydroxyapatite samples ranged from 21.32 ms at a concentration
of 189.70 mg/mL to 44.76 ms at 74.90 mg/mL (Table 3.10).

The iron oxide signal levels within this phantom were all negligible, and no change was noted
with TE (Figure 3.15). These signal levels were too low to provide an accurate assessment of
the T2* for the samples.

Figure 3.14: Hydroxyapatite signal in the high concentration preliminary phantom by
echo time (TE). The normalized signal shows a clear concentration dependence in the
decay rate of the signal with TE.
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Figure 3.15: Iron oxide signal in the high concentration phantom shows a low signal at all
echo times for all concentrations of iron oxide present.
Table 3.10: T2* values for hydroxyapatite samples of varying concentrations. The mean
signal over five images was used to calculate T2*.
Hydroxyapatite
Concentration
(mg/mL)
74.9
107.8
124.2
140.5
173.3
189.7

Calculated T2* (ms)

44.76
33.42
32.00
28.50
22.78
21.32

3.3.2 Hydroxyapatite and Iron Dextran Phantoms
Approximately Matched SECT HU Phantom (R1)
The round phantom design minimized the signal loss caused by the air-phantom boundary by
increasing the space between the samples and the outer edge of the phantom. The iron
dextran tested in this phantom showed T1 shortening, indicated by the bright initial signal on
the first echo of the MFGRE, and chemical shift artifact (black band above sample) at very high
concentrations of iron dextran (Figure 3.16 a). Despite the high initial signal, the iron dextran
displayed significant T2* decay, which was evident as the TE increased (Figure 3.16 b and c).
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The hydroxyapatite samples were present in higher concentrations than in previous phantoms,
and complete signal dropout was accomplished at later echoes (Figure 3.16 c).

Figure 3.16: MFGRE magnitude images of an iron dextran (ID) and hydroxyapatite (HAP)
phantom with the round design; sample concentrations are given in mg/mL for HAP and
mg Fe/mL for ID. Iron dextran is on the top half and hydroxyapatite on the bottom half, as
indicated by the white line in (a). The iron dextran displays T1 shortening (bright signal),
and a chemical shift is present in high concentrations, indicated by the cyan circle (a).
Signal remains present in several iron dextran samples at the third (b), and fifth (c) echoes
and higher concentrations of hydroxyapatite were tested to decrease the T2* further
relative to prior phantoms.
Quantitatively, the iron dextran signal at the lowest TE varies, in large part due to the T1 effects
seen in the phantom images. The highest concentration (32.41 mg Fe/mL) had complete signal
dropout by a TE of 19.5 ms (Figure 3.17), but enough signal was present in the prior echoes to
measure T2*. The relaxation rate is a function of the iron dextran concentration, with a T2* of
86.92 ms at 0.59 mg Fe/mL down to 3.45 ms at 32.41 mg Fe/mL (Table 3.11). Notably, the
hydroxyapatite samples had a similar range of T2* as the iron dextran (7.62 – 49.68 ms).

DECT analysis was performed in this phantom to the iron- and calcium-based lesions because
the SECT HU values were intentionally matched between the iron dextran and hydroxyapatite.
Plotting the mean water(calcium) and calcium(water) values show that the materials are not
separable using this material decomposition Figure 3.19.
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Figure 3.17: MFGRE signal changes with increasing echo time (TE) for iron dextran
samples in a round phantom. Signal normalized to the first TE is displayed in the plot at
the bottom to emphasize the concentration dependence of the signal decay.
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Figure 3.18: MFGRE signal changes with increasing echo time (TE) for hydroxyapatite
samples in a round phantom. Signal normalized to the first TE is displayed in the plot at
the bottom to emphasize the concentration dependence of the signal decay.
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Table 3.11: Calculated T2* for iron dextran and hydroxyapatite in a phantom with
approximately matched SECT HU ranges.
Iron Dextran
Concentration
(mg Fe/mL)
0.59
1.77
3.54
5.89
8.25
10.61
11.79
14.15
32.41

SECT
Attenuation
(HU)
8.72
11.77
19.33
44.30
67.49
75.90
78.23
94.72
218.53

Calculated
T2* (ms)
86.92
49.60
29.58
11.80
7.36
6.71
6.68
5.22
3.45

Hydroxyapatite
Concentration
(mg/mL)
13.22
24.82
42.24
48.00
59.53
74.16
117.61
146.51
194.24

SECT
Attenuation
(HU)
22.85
39.19
66.65
75.96
87.05
112.56
178.84
231.32
326.78

Calculated
T2* (ms)
49.68
51.96
29.91
28.64
24.50
20.18
12.58
10.01
7.62

Figure 3.19: DECT calcium/water material decomposition data for iron dextran and
hydroxyapatite samples. Note that sulfur is present in the iron dextran complex, which is
not present amongst biological hemorrhage.
Biological T2* Phantom (R2)
This phantom demonstrated that iron dextran concentrations could be adjusted to create lesion
models with biological levels of T2*. Lowering the concentration also had the added benefit of
eliminating the chemical shift artifact that was seen in the vial with the most dextran complex in
59

the previous phantom (Figure 3.16). The ranges of the calculated T2* for the iron dextran and
hydroxyapatite lesions, respectively, were found to be 30.44 – 89.49 ms and 5.53 – 42.22 ms
(Table 2.2, Figure 3.20, Figure 3.21). The T2* values for hemorrhagic lesion models are in
agreement with the literature values for iron-laden gray matter (4.1 – 62.5 ms) (209) and
cavernomas (211), while the hydroxyapatite samples covered nearly the full range of T2* (9 –
50 ms) found in calcifications by Roy et al. (212).
Table 3.12: Calculated T2* from the monoexponential fits for various concentrations of
iron dextran and hydroxyapatite in a phantom with biological susceptibility levels.
Iron Dextran
Concentration
(mg iron/mL)
0.4
0.8
1.2
1.6
2
2.4
2.8
3.2
3.6

Calculated
T2* (ms)
89.49
80.85
63.82
49.26
45.48
42.03
37.96
33.60
30.44

Hydroxyapatite
Concentration
(mg/mL)
7.8
15.7
23.5
31.4
39.2
58.8
78.4
137.3
196.1

Calculated
T2* (ms)
42.22
23.81
17.52
13.01
10.00
8.94
7.56
6.83
5.53
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Figure 3.20: MFGRE signal and normalized signal for hydroxyapatite with biological T2*
levels. The T2* ranges from 5.53 to 42.22 ms in this phantom.
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Figure 3.21: MFGRE signal and normalized signal for iron dextran with T2* values within
the range expected in normal gray and white matter. The T2* in this phantom ranges from
30.44 to 89.49 ms.
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3.3.3 Calcium Chloride Phantom (R3)
The MFGRE signal decay curves for the serial dilutions of calcium chloride in this phantom
experiment are shown in the figure below (Figure 3.23). Low T2* is indicative of faster signal
dephasing due to magnetic field inhomogeneities. Overall, hydroxyapatite had a lower T2* to
SECT attenuation ratio (Figure 3.22), making it more similar to calcification than the calcium
chloride.

Figure 3.22: Calculated T2* versus the SECT attenuation of the hydroxyapatite and
calcium chloride gels. The T2* of the calcium chloride is higher than that of the
hydroxyapatite for all SECT levels investigated.
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Figure 3.23: MFGRE magnitude signal for various concentrations of calcium chloride with
and without signal normalization
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3.3.4 Iron Oxidation State Phantom (R4)
The 0.4 mg Fe/mL concentration of iron(II) chloride was excluded from analysis due to the
presence of an air bubble. Qualitatively, the signal of the iron(II) chloride was generally higher
than that of the iron(III) chloride for the same amount of iron present. The signal of each
material was concentration dependent, but the decrease in the normalized signal was greater
for iron(III) than iron(II) (Figure 3.24, Figure 3.25).

The iron oxidation state of iron was shown to change the calculated T2* relaxation time for
equal concentrations of iron particles. The ranges of calculated T2* for iron(II) chloride and
iron(III) chloride were 84.96 – 777.14 ms and 4.01 – 90.53 ms, respectively. Both compounds
demonstrated monotonically decreasing T2* with increasing iron concentration.
Table 3.13: Calculated T2* for various concentrations of iron(II) chloride and iron(III)
chloride in a phantom. The 0.4 mg Fe/mL iron(II) chloride sample was excluded due to the
presence of an air bubble.
Iron (II) Chloride
Concentration
(mg Fe/mL)
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6

Calculated
T2* (ms)
777.14
190.31
133.91
117.55
105.89
101.34
84.96

Iron(III) Chloride
Concentration
(mg Fe/mL)
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6

Calculated
T2* (ms)
90.53
30.11
15.63
10.57
7.31
5.67
4.87
4.01
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Figure 3.24: Iron(II) Chloride MFGRE signal data. Units of concentration are given in mg
Fe/mL. Note that while there is a concentration dependence in the normalized plot, there
is relatively little signal dropout even at high concentrations.
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Figure 3.25: Iron(III) chloride MFGRE signal curves. Units of concentration are given in mg
Fe/mL. There is a large signal dropout at high iron concentrations that are not seen when
the iron is in the 2+ oxidation state.
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3.3.5 Final Biological Phantoms
Calibration Phantom (RF1)
Multiple materials were made to span the clinical range of expected T2* values in patients. Of
the iron containing lesion models, hemoglobin had the highest T2*, followed by iron dextran
and iron(III) chloride (Table 3.14). This range is highly desirable in a single phantom because
there may be multiple categories of hemorrhage (acute, subacute, chronic, etc.) imaged within
a clinical trial. The standard deviation of the T2* calculated from three different MFGRE
acquisitions was very low (0.02 – 0.45 ms), indicating good repeatability. The normalized signal
curves for each material are found in Figure 3.26 a-d.

Table 3.14: Mean ± standard deviation of the T2* calculated for three acquisitions of the
MFGRE.

Hydroxyapatite

Iron Dextran

Iron(III)
Chloride

Hemoglobin

Conc.
(mg/mL)

181.8

210.3

238.7

267.4

T2* (ms)

8.74 ± 0.03

7.66 ± 0.08

7.07 ± 0.10

6.40 ± 0.22

Conc.
(mg Fe/mL)

0.7

1.4

2.1

2.8

T2* (ms)

57.85 ± 0.15

44.28 ± 0.06

Conc.
(mg Fe/mL)

0.31

0.62

0.94

1.25

T2* (ms)

12.04 ± 0.02

5.09 ± 0.04

3.39 ± 0.04

3.11 ± 0.12

Conc.
(mg Fe/mL)

0.17

0.34

0.42

0.66

T2* (ms)

128.98 ± 0.45

75.85 ± 0.24

35.96 ± 0.06 30.87 ± 0.02

74.21 ± 0.17 16.13 ± 0.04
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Figure 3.26: Normalized MFGRE signal curves for a) hydroxyapatite, b) iron(III) chloride),
c) iron dextran, and d) human hemoglobin.
Biological Phantom with Mixed Materials (RF2)
Voxel-wise T2* fitting of ROIs within each sample returned T2* values between 3.92 ms and
80.86 ms. The mean and standard deviation of the T2* for each mixture is located in Table
3.15. Displaying the ROIs in a single plane (Figure 3.27) demonstrates the presence of the
hydroxyapatite lesions (upper left) within four samples of iron dextran. The mixtures did not
display large non-uniformities, and the standard deviations in the T2* measurements were
small.

69

Figure 3.27: Voxel-wise T2* calculations for each sample displayed in the same plane
along the z-axis. The four vials labeled ID/HAPm have an iron dextran background and
hydroxyapatite masses, and additional analysis was performed for these samples.

Figure 3.28: An example of the histogram analysis for the iron dextran samples that
contained hydroxyapatite masses. A kernel density estimate (black line) was fit to the data
to estimate the mean T2* of the background and mass. This suggests that voxel-wise
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histogram analysis of T2* might contain characterizing information that could be used
clinically.
Table 3.15: Mean and standard deviation of each mixture or sample without visible mass
for the voxel-wise calculation of T2*.
Lesion Model Mean T2* (ms) Standard Deviation (ms)
HAP/ID 1

10.00

1.41

HAP/ID 2

7.58

0.44

HAP/ID 3

11.69

0.84

IC/ID 1

6.14

0.28

IC/ID 2

8.58

0.38

IC/ID 3

18.51

0.72

Hb/ID 1

48.54

2.38

Hb/ID 2

29.01

1.10

IC/IDm

9.46

1.06

ID/IDm 1

48.04

3.11

ID/IDm 2

48.54

2.38

ID/IDm 3

45.22

4.01

Table 3.16: T2* estimates for lesions containing masses, resulting from the biexponential
fit of the ROI means and the peak location of the T2* kernel density estimate for the voxelwise calculations.

Lesion

Biexponential Fit

Kernel Density

Biexponential Fit Error

Estimate

𝑻𝟐∗ 𝟏

𝑻𝟐∗ 𝟐

Peak 1

Peak 2

𝑻𝟐∗ 𝟏 Err.

𝑻𝟐∗ 𝟐 Err.

(ms)

(ms)

(ms)

(ms)

(ms [%])

(ms [%])

ID/HAPm 1

3.58

34.17

8.38

39.33

-4.80 [-57%]

-5.16 [-13%]

ID/HAPm 2

7.87

47.26

10.75

48.45

-2.88 [-27%]

-1.19 [-2.5%]

ID/HAPm 3

7.09

62.21

8.91

59.46

-1.82 [-20%]

2.75 [4.6%]

ID/HAPm 4

10.74

89.72

9.34

52.86

1.40 [15%]

36.86 [70%]

Model

For the four lesion models with masses that were apparent on the T2* map (ID/HAPm 1-4,
Figure 3.27), the results of the biexponential fitting and kernel density estimate (example in
Figure 3.28) are displayed in Table 3.16. The estimates from the biexponential fit were within
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approximately 5 ms of the T2* calculated from the peaks of the histogram’s kernel density
estimate. Overall, a linear fit of the estimated T2* values from the biexponential fit versus the
peak locations of the voxelized T2* calculations had an R 2 value of 0.849, indicating that the
two analysis methods were correlated (Figure 3.29). The biexponential fit of the higher T2*
peak from the iron background did not fit well, and there was a 70% overestimate of the T2*.
However, the mass was angled so that there was very little background in the ROI, and the
higher peak was not evident in the histogram.

Figure 3.29: A linear fit of the T2* estimates resulting from the voxelized (kernel density)
and ROI-based (biexponential fit) T2* estimates for iron dextran lesions with
hydroxyapatite masses demonstrates correlation between the two analysis methods.

3.4

Discussion

The goal of this study was to validate materials for an MRI phantom of calcific and hemorrhagic
lesion models and construct a final phantom with T2* properties within biological constraints.
We determined that separate phantoms were required for DECT and PS-MRI. We analyzed
two calcium-containing compounds—hydroxyapatite and calcium chloride—and five iron
compounds, including iron(III) oxide, iron dextran, iron(II) chloride, iron(III) chloride, and human
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hemoglobin. Out of these materials, the final MRI phantom was made from hydroxyapatite, iron
dextran, iron(III) chloride, and hemoglobin.

One of the original goals of this work was to find a compound that could be used for both an
MRI phantom and DECT phantom at the same concentrations. This goal was not met because
that MRI is significantly more sensitive to the presence of paramagnetic materials such as iron
than is CT. Concentrations of iron oxide high enough to mimic the appearance of hemorrhage
on SECT and DECT (utilized by Nute et al. (135)) induced significant artifacts on T2*-weighted
pulse sequences, and demonstrated virtually no signal at the TEs examined. Since iron oxide is
not soluble in water, it would have been difficult to lower the concentration further compared to
what was used in the lower concentration phantom. Therefore, iron oxide was eliminated as a
possibility for modeling hemorrhagic lesions on MRI.

Since one of the primary drawbacks of using iron oxide in an MR phantom was insolubility in
water, we focused on utilizing iron compounds that were easily dissolved is water. While many
studies have used superparamagnetic iron oxide nanoparticles, as found in ferumoxytol
(Fereheme; AMAG Pharmaceuticals, Waltham, MA), these would feature a very high magnetic
susceptibility for a given iron concentration, and thus were ruled out. Instead, we chose to use
iron dextran, another compound, like ferumoxytol, that is used to treat anemia intravenously.
Iron dextran is soluble in water, and at appropriate concentrations (0.4 – 5.6 mg Fe/mL), was
shown to have T2* values consistent with the literature for pathologically iron-laden tissues. It
should be noted that this compound did shorten T1, so care must be taken to use this in
phantoms appropriately since it will not adequately simulate the T1 properties of hemorrhage.

Iron chlorides were yet another option for an MR hemorrhage model. Iron exists in both the 2+
and 3+ oxidation states in the body (218, 219), and hematomas exhibit different T2* properties
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as the lesion progresses from acute to chronic states and the density and oxidation states
change (3, 26, 220). Chronic hemorrhage, heavy in the iron storage proteins hemosiderin and
ferritin, and most forms of hemoglobin primarily contains iron in the more stable 3+ oxidation
state (218, 219). Since Fe2+ can bind oxygen, it is primarily located in deoxyhemoglobin in
patients with normal iron metabolism; however, when Fe2+ is found outside in tissues, it can
induce tissue damaging free radical formation (220-222). This potential for iron-related damage
to normal brain tissue due to disordered iron metabolism may be a factor in certain neurological
diseases such as Parkinson’s disease (221-223). However, due to the possibility that we may
see more than one stage of hemorrhage or iron deposition due to multiple etiologies, we
investigated the use of both iron(II) and iron(III) chloride in phantoms. We found that iron(II)
chloride had a much higher T2* at similar iron concentrations compared to iron(III) chloride.
Studies in the literature indicate that at a magnetic field strength of 3.0 T, the T2* of normal
tissues ranged from 13.8 to 45.5 ms in seven male cadavers (age 38-81 years, mean age 52.3
years) (209, 224). In comparison to those biological values, the lowest T2* found in the iron(II)
chloride samples was 84.96 ms. Therefore, we excluded iron(II) chloride from subsequent
phantoms and analysis.

Iron dextran was investigated for potential use as a DECT phantom material, but we found that
adequate separation of the hydroxyapatite and iron dextran was not possible using the
methods developed by Nute et al. (135). Iron oxyhydroxide, which contains sulfur, is the
primary iron-containing compound in iron dextran (225). The addition of sulfur increases the
attenuation due to photoelectric effect compared to the iron-containing compounds found in the
body (226). Despite the lack of translation of an iron compound from CT to MRI phantoms,
hydroxyapatite—also utilized by Nute et al.—was the material selected to model calcific lesions
over calcium chloride. Calcium chloride did not demonstrate a T2* value comparable to clinical
studies for a given SECT HU (212). Hydroxyapatite does have limitations, however. The
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material is not soluble in water, and therefore must be carefully emulsified, typically overnight,
and manually shaken to achieve uniformity in agarose gels. While a magnetic stir bar was used
to aid the emulsification process, adequate emulsification was not possible when
concentrations exceeded approximately 275 mg/mL.

The final phantoms utilized for the study were comprised of hydroxyapatite, iron dextran,
iron(III) chloride, and lyophilized human hemoglobin (as a biological reference). The MFGRE
and SWAN data acquired for these two phantoms will be used in a future analysis (see Chapter
4). The calibration phantom will allow for direct comparisons of iron and calcium content in
human tissue based on comparisons of the T2* and eventually magnetic susceptibility (See
Chapter 4 for an evaluation of phase-sensitive MR techniques in these phantoms). The second
of these biological phantoms features mixed lesions with various combinations of iron and
calcium compounds as well as vials containing masses of other materials within a uniform
background containing iron. It is particularly important to assess how well susceptibility
mapping maintains lesion sizes in the presence of high susceptibility lesions, and we plan on
testing this in phantom RF2. We showed in this chapter that lesions with masses featuring two
dramatically different T2* values are best modeled using a voxel-wise analysis of the relaxation
parameters. However, a biexponential fit of the mean signal across TEs provides a better fit
than a monoexponential, and can potentially be used to estimate the two T2* values to within
approximately 5 ms. Using this additional analysis may be useful to determine whether lesions
in patients may contain more than one compound or density.

In making the final phantoms (Phantoms RF1 and RF2), there were several limitations.
Hemoglobin is soluble in water to 20 mg/mL, but to adequately match the concentrations found
in human blood, higher concentrations were necessary. Therefore, hemoglobin was the only
material dissolved in Lactated Ringer’s solution, which increased the solubility to over 200
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mg/mL. There may be slight differences in the T2* calculations caused by changing the
background material from agarose, which itself modifies T2 proportionally with its viscosity
(227, 228). In the final phantom with mixed lesions, the concentration of the background
agarose was raised to 2% weight/volume to keep the material in the masses, particularly the
iron compounds, from bleeding into the surrounding agar background. However, this caused
the agarose to solidify quickly, and several of the masses were mispositioned in the vials and
could not be adequately imaged. The masses of the most interest, the calcific masses
surrounded by iron dextran, were all readily visible, and so forming new samples and
rescanning was deemed unnecessary.

We also limited the data used in the T2* calculations for all but the final phantom to the mean
over five images per vial. The T2* calculations in the final phantom were based on calculations
for each voxel within an ROI. While this voxelized T2* mapping is possible and provides
additional information about the spatial variation in T2*, since the majority of the phantoms
were meant to validate the general MR properties of the materials with a simple methodology,
we did not undertake this more computationally intensive analysis in every phantom at this
point.
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Chapter 4

4

4.1

Magnetic Resonance Imaging Acquisition and Processing

Introduction

As discussed in Section 2.5, T2*-weighted Gradient Recalled Echo (GRE) pulse sequences are
highly sensitive to changes in the magnetic susceptibility of tissues. It is the most commonly
utilized sequence in the clinic for identifying chronic intracranial bleeds, cerebral microbleeds,
and iron deposits. These lesions appear as black spots, representative of signal loss, and are
known as “foci of susceptibility.” However, the specificity of this image type is limited since
calcific lesions appear identical to hemorrhage due to their low proton density and diamagnetic
characteristics.

The goal of this study was to utilize the phantoms developed in Chapter 3 to determine which
pulse sequences and post processing algorithms provided the highest specificity for
distinguishing calcification and hemorrhage. The methods investigated for this purpose include
susceptibility weighted angiography (SWAN) sequence filtered phase images, background
subtracted phase images from Projection onto Dipole Fields (PDF), and quantitative
susceptibility mapping (QSM).

4.2

Methods

4.2.1 Phantoms
The phantoms used for this study included phantoms RF1 and RF2 from Chapter 3.3.5.
Phantom RF1 provided calibration data for hydroxyapatite, iron dextran, iron(III) chloride, and
hemoglobin at various concentrations (Table 3.5). Phantom RF2 focused on mixtures of the
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materials present in RF1 as well as testing the feasibility of differentiating small calcific masses
from hemorrhage models (Table 3.6).
4.2.2 MRI Scan Prototcol
All phantom imaging was performed on a 3.0-T MRI system (MR 750, General Electric
Healthcare) with an 8-channel head coil. The phantoms were positioned with the vials parallel
to B0 to minimize blooming. A three-dimensional (3D) T1-weighted ultrafast gradient echo with
magnetization preparation (IR-FSPGR) was acquired to assess geometric accuracy near the
vials. 3D susceptibility-weighted angiography (SWAN) sequence was acquired to examine the
background phase—which is automatically reconstructed—in each material, and we acquired a
3D multi-echo fast gradient recalled echo (MFGRE) for generating both background-subtracted
phase imaging with PDF and susceptibility distributions from QSM. Protocol details are in Table
4.1. The SWAN and MFGRE sequences were each acquired three times to check the
repeatability of the test metrics.
Table 4.1: MRI acquisition details for all phantom experiments, including repetition time
(TR), inversion time (TI), receive bandwidth (BW), field-of-view (FOV), acquisition matrix
Sequence

IR-FSPGR

3D SWAN

3D MFGRE

# of Echo Times

1

6

12

TE (ms) [min, max]
2.1
23.3a
[4.7, 61.4]
TR (ms)
5.7
37.6
65.2
TI (ms)
400
Flip Angle
20°
15°
20°
BW (kHz)
128
128
128
FOV (mm)
220
220
220
Phase FOV (% of FOV)
80
80
80
Matrix
256 x 256
320 x 224
416 x 320
Slice Thickness (mm)
1.4
1.4
1.4
Scan Time
4:27
2:49
6:46
a
SWAN provides images that are a weighted average of the six echoes. The average TE is
listed here.
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4.2.3 Phase-Sensitive MR Post-Processing
Post-processing of the SWAN sequence was performed at the scanner by selecting the option
to reconstruct a high-pass filtered phase image from the k-space data. Real, imaginary, and
magnitude images were generated for all echoes of the MFGRE pulse sequence at the
scanner; additional processing for the MFGRE was performed on an external workstation (2.8
GHz Dual-Core Opteron Processor 8220 (Advanced Micro Devices, Santa Clara, CA) with up
to 128 GB of RAM). The phase data was calculated from the real and imaginary images; a
temporal phase unwrapping algorithm developed by Kressler et al. was used to calculate a
map of the measured magnetic field (180, 183). Aliased frequencies in the magnetic field map
were removed using the method described by Liu et al. (183). The final background-removed
phase image was calculated using the Projection onto Dipole Fields (PDF) method (154), which
eliminated phase shifts caused by non-local susceptibility effects (i.e., the air-phantom
boundary). The resulting field map from the PDF was used as an input to morphology-enabled
dipole inversion (MEDI) QSM processing (167, 182), which returned a map of the magnetic
susceptibility within the phantom in units of parts per billion (ppb).
4.2.4 Image Analysis
Phantom RF1
For each acquisition, regions-of-interest (ROIs) were defined for each vial on five consecutive
images to create larger volumes-of-interest (VOIs). The same VOIs were applied to the SWAN
filtered phase images, the PDF results, and the QSM images. The mean of each VOI was then
calculated for a given acquisition. The standard deviation of the VOI mean over three
acquisitions was calculated for each sample and image type. Calibration curves for each image
type and material were defined by linear regression of the signal versus material concentration
(in mg/mL for hydroxyapatite and mg Fe/mL for iron-containing samples).
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Phantom RF2
In phantom RF2, VOIs were defined spanning five consecutive images within each sample.
The mean and standard deviation in the VOI across the three acquisitions were calculated. By
plugging the known composition of each lesion model into the QSM calibration curves and
taking the sum of the two material susceptibilities, we determined whether the expected
susceptibilities were additive. The percent error was calculated relative to the predicted value.
The diameter of a hydroxyapatite masse located within a hemorrhagic model (ID/HAPm 1) was
measured on both the IR-FSPGR and QSM images to determine the geometric accuracy of the
QSM images. The measurements were made by placing a line profile across the widest portion
of the hydroxyapatite mass in five consecutive images. The diameter was calculated using the
full width half max (FWHM) of the mass for both image types. The percent error was calculated
relative to the IR-FSPGR, which has better geometric accuracy than the MFGRE pulse
sequence that the QSM is based on.
4.2.5 Statistical Analysis
In phantom RF1, the mean values of the defined VOI for each acquisition were grouped into
categories of hemorrhagic or calcific lesion models. Receiver operating characteristic (ROC)
analysis was performed to determine the optimal threshold between the diamagnetic
hydroxyapatite samples and the paramagnetic iron samples. The diameters of the
hydroxyapatite mass as measured on the IR-FSPGR and QSM sequences were compared
using a two-sided Student’s t test with α = 0.05.

4.3

Results

4.3.1 Phantom RF1 Analysis
The mean and standard deviation within each sample is reported in Table 4.2. In the
hydroxyapatite samples, linear fits of the SWAN filtered phase, PDF, and QSM had negative
slopes with hydroxyapatite concentration (Figure 4.1). While the SWAN phase demonstrated a
negative trend with increasing hydroxyapatite content, the R2 was only 0.437, and the phase
80

does not decrease monotonically. For linear fits of the same VOIs on PDF and QSM images,
the R2 values were 0.927 and 0.830, respectively, which indicated a tighter relationship with
concentration than for the SWAN filtered phase images. In the iron-containing samples, SWAN
filtered phase images also demonstrated poor fits with iron concentration for all three materials
tested (Figure 4.2). The slope of the fit for hemoglobin was also negative while the fits for iron
dextran and iron(III) chloride were positive, making it difficult to distinguish between potentially
diamagnetic and paramagnetic materials (Figure 4.2a). In the iron-containing samples, PDF
and QSM both had better fits overall than the SWAN phase images. However, QSM processing
had a much tighter fit for the iron(III) chloride samples (R2 = 0.972) than PDF did (R2 = 0.367).
This difference may be attributable to the spherical mean value (SMV) processing used within
the QSM algorithm that is not used on the final PDF image. SMV computes the mean of a
sphere several voxels in diameter for all voxels within the image, which effectively eliminates
outlier voxels within uniform regions of the phantom (229).

Figure 4.1: SWAN filtered phase (in mrad), PDF (in mrad), and QSM (in ppb) means for the
hydroxyapatite samples. Error bars represent the standard deviation in the mean value
across three acquisitions.
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Table 4.2: Mean and standard deviation in phantom RF1 for the SWAN filtered phase, PDF,
and QSM images. Concentration for hydroxyapatite is given in untis of mg/mL while ironcontaining compounds are reported in mg Fe/mL. Values marked by an asterisk have high
variability between acquisitions and correspond with the samples with the highest
magnetic susceptibility in the phantom.

Hydroxyapatite**

Iron(III)
Iron Dextran Hemoglobin
Chloride

Compound

Concentration
(mg Fe/mL or
mg/mL**)
0.17
0.34
0.42
0.53
0.70
1.40
2.10
2.80
0.31
0.62
0.94
1.25
181.8
210.3
238.8
267.4

SWAN Filtered
Phase (rad)

PDF (ppb)

QSM (ppb)

82.1 ± 3.9
-63.3 ±4.2
168.9 ± 19.6
-304.4 ± 16.8
7.6 ± 0.7
-54.0 ± 4.0
68.2 ± 4.9
5.0 ± 8.2
35.3 ± 2.3
-21.6 ± 19.4
11.0 ± 75.7
53.2 ± 1.8
-15.9 ± 26.3
168.7 ± 38.4
-397.7 ± 19.9
-256.7 ± 9.3

174.6 ± 0.6
307.5 ± 1.1
366.9 ± 1.0
695.2 ± 0.9
628.9 ± 1.4
1215.3 ± 3.8
1829.4 ± 2.4
2414.6 ± 4.9
1007.4 ± 2.9
2475.2 ± 20.9
1675.2 ± 9464.3*
3501.2 ± 920.6*
-216.9 ± 1.9
-223.6 ± 3.3
-290.0 ± 7.6
-334.9 ± 40.0

232.3 ± 5.4
436.6 ± 7.0
461.5 ± 7.3
643.5 ± 5.7
738.4 ± 1.6
1349.4 ± 8.5
2071.5 ± 14.0
2536.1 ± 31.3
862.9 ± 5.5
2072.4 ± 24.9
837.2 ± 3054.8**
3363.8 ± 407.4**
-167.7 ± 4.7
-157.1 ± 10.3
-210.6 ± 12.8
-250.6 ± 7.5
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Figure 4.2: Hemoglobin, iron dextran, and iron(III) chloride signal on a) SWAN filtered
phase, b) PDF, and c) QSM images versus iron concentration. The error bars represent
the standard deviation of a VOI measurement across three acquisitions. Note that the
mean and standard deviation in an iron(III) chloride samples with the highest iron
concentration each excluded an extreme outlier in both the PDF and QSM fits (see Figure
4.3).
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Figure 4.3: Images of phantom RF1 demonstrate the impact of poor phase unwrapping in
the PDF and QSM processing for an iron(III) chloride sample (yellow circles). The
acquisition shown in the top row shows a primarily positive phase on PDF (a) with some
residual phase wraps, but a positive QSM proportional with its iron concentration (b). The
bottom row is another acquisition in the same scan session where the phase has a 2π
shift in the PDF (c), and thus the estimated susceptibility was negative (d).
4.3.2 Phantom RF2 Analysis
The predicted susceptibility for each mixture within the phantom is given in Table 4.3. The
percent errors relative to the predicted value were very high for all material combinations
except that of iron(III) chloride and iron dextran, which had a maximum error of 20.4%.
Therefore, we have experimentally verified that susceptibility is not an additive quantity in these
lesion types in most cases.

84

Table 4.3: Predicted susceptibility based on the mixture concentrations in phantom RF2
input into the calibration curves for QSM defined in Phantom RF1. These values were
compared to the measured susceptibility in the mixtures, and the percent error was
calculated
Label
HAP/ID 1
HAP/ID 2
HAP/ID 3
IC/ID 1
IC/ID 2
IC/ID 3
Hb/ID 1
Hb/ID 2

Predicted
Susceptibility
1798.0
1186.5
575.0
1877.7
1771.7
1691.3
1172.5
1290.8

Measured Susceptibility
(ppb)
870.1 ± 0.5
806.3 ± 45.2
276.3 ± 46.2
1897.6 ± 47.4
1634.4 ± 49.9
1345.9 ± 3.2
697.5 ± 0.8
858.3 ± 5.7

Percent Error (%)
-51.6 ± 0.1
-32.0 ± 3.8
-51.9 ± 8.0
1.1 ± 0.2
-7.7 ± 0.1
-20.4 ± 0.4
-40.5 ± 2.5
-33.5 ± 2.8

The diameter of a hydroxyapatite lesion was assessed using FWHM measurements on the IRFSPGR and QSM image sets. The mean diameter (± one standard deviation) was 5.04 ± 0.11
mm on the IR-FSPGR and 3.14 ± 0.13 mm on the QSM. The measured diameter on QSM was
1.90 mm (95% confidence interval: [1.79,2.02]), and the difference was statistically significant,
with a p-value < 0.001.
4.3.3 Statistical Analysis
Histograms of the individual VOI means for all iron-containing samples (red), and
hydroxyapatite samples (blue) in Phantom RF1 and RF2 are shown in Figure 4.5. The optimal
threshold to differentiate between the calcific and hemorrhagic lesion models were determined
to be -69.9 mrad, 174.0 mrad, and 228.0 ppb for SWAN filtered phase, PDF, and QSM images,
respectively. These thresholds resulted in a sensitivity values of 91.7%, 97.2%, and 97.2% and
specificity values of 50.0%, 100%, and 100% for the three image types. PDF and QSM had
identical performance metrics (AUC = 0.972) since there was a single iron measurement that
was a known outlier (Figure 4.3, Figure 4.5) caused by an error in phase unwrapping. In
contrast, the SWAN phase data returned an AUC of 0.644 (Figure 4.4).
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Figure 4.4: ROC analysis for SWAN filtered phase, PDF, and QSM data. The threshold
indicates the threshold for which the sum of the true positive rate and the false negative
rate were optimized. AUC is defined as the area under the curve.
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Figure 4.5: Histograms of the mean in all calcific and hemorrhagic lesion models over
three acquisitions for SWAN filtered phase (a), PDF (c), and QSM (e) data. Representative
images of phantom RF1 are included for the three image types: b) SWAN Phase, d) PDF
and f) QSM. The colored polygons indicate the material within the samples:
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hydroxyapatite (blue), iron dextran (red), iron(III) chloride (green), and hemoglobin (gold).
Units for the SWAN and PDF images are milli-radians; QSM is in units of ppb. One iron(III)
chloride sample (green arrows) had errors in the phase unwrapping (d), which were
improved in the QSM (f).

4.4

Discussion

We found than the QSM had the best correlation with material concentration out of the three
image types tested. There have been several studies demonstrating that the susceptibility of
iron relative to water is between 0.55 and 1.30 ppb per ppm (by mass) of iron in wet tissue
(176, 209, 224) or approximately 0.14 ppb per ppm iron in dry tissue (230). Since 1 mg Fe/mL
is equal to 1000 ppm, the slopes calculated in the calibration curves in this study represented
1.10, 0.87, and 2.57 ppb of susceptibility per ppm of iron for hemoglobin, iron dextran, and
iron(III) chloride, respectively. This is largely in agreement with the literature studies in humans.

As shown in Figure 4.5b, the SWAN filtered phase images do not provide sufficient phase
unwrapping as far as 4 cm away from the edge of the phantom. There was not a large enough
uniform region to determine if the phase would change monotonically with concentration were
they more centrally located. While ideally a larger phantom would be used to counteract this
problem with the phase non-uniformities, the size of the head coil limits the overall size of the
phantom. Patient images that fail to have complete phase unwrapping may limit the capacity of
radiologists to differentiate between diamagnetic and paramagnetic materials, as it has within
this phantom. The default SWAN filtered phase images themselves have not been reported on
extensively in the literature. However, similar sequences from other vendors have
demonstrated significant phase aliasing in lesions when the phase is processed with a high
pass filter (144, 231).

In comparison to the SWAN filtered phase images, both the PDF and QSM signal correlated
much better with material concentration for all material types. The signal within PDF images is
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proportional to the local magnetic field changes (relative to the main magnetic field) caused by
the presence of the phantom; in comparison, the QSM signal is equal to the inherent magnetic
susceptibility of the materials in a given voxel. Because the presence of a material with a large
susceptibility causes changes in the local magnetic field, they are closely related. However,
due to the dipole moment of a susceptibility source, there are phase differences in the
surrounding material that are caused by the susceptibility source some distance away. The
non-local phase effects can lead to artifacts around the vials in the PDF images (Figure 4.5d)
that are removed during QSM processing (Figure 4.5f). Therefore, the overall image quality of
the QSM may be higher than that of the PDF.

Problems with phase unwrapping also impacted portions of the PDF and QSM processing
pipeline in specific circumstances. In one iron(III) chloride sample with relatively high
susceptibility, the PDF presented with a phase shift of 2π in one of the three acquisitions. This
translated to a measured susceptibility in the lesion model where the magnitude of the
susceptibility was correct, but the sign was negative. The issue was traced back to an error in
the phase unwrapping of the initial field map, which affected both the PDF and QSM. Since
lesions with lower and higher concentrations of the material were successfully unwrapped, we
assume that this is a problem only at specific susceptibility levels that cause aliasing in the field
map frequency. In the literature, it has been documented that acute hemorrhage featuring
primarily deoxyhemoglobin has a maximum susceptibility of approximately 1.60 ppb (232); in
comparison, this lesion had an estimated susceptibility of 2.50 ppb. In phantoms, we will be
able to develop an algorithm to correct this issue. However, since the composition of lesions
within the body is not known a priori, it will be difficult to implement in patient exams without
additional testing. Adjusting the pulse sequence parameters may be a better long term solution
to avoid phase aliasing within the expected frequency range.
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We found very good agreement in the QSM across acquisitions. In phantom RF1, the largest
standard deviation across acquisitions—in all but those samples with uncorrected phase
wraps—was 31.3 ppb. One study performed QSM in two normal volunteers that were scanned
at 10 different sites, and in the tissues evaluated, the intra-subject coefficient of variation was
under 10% (233). Since that study only evaluated healthy patients, they measured a maximum
susceptibility of approximately 0.14 ppm; in comparison, the highest susceptibility in this study
(without phase aliasing) was 2.54 ppm to represent an acute or chronic hemorrhage (233). The
variance in our study increased with higher iron levels, so in patients with lesions, the
coefficient of variation may increase.

In phantom RF2, we investigated whether we could predict the susceptibility of a lesion by
summing the calibration curve-derived susceptibility of multiple materials. This simple phantom
experiment demonstrated that even in a controlled environment, the susceptibility of multiple
materials is not an additive quantity. Since the susceptibility is proportional to the number of
free electrons in a material, mixing materials increases the chance of interactions that will bind
free electrons, hence modifying the susceptibility properties. An example of the phenomenon is
that while we would expect that mixing diamagnetic hydroxyapatite with paramagnetic iron
dextran would lower the overall susceptibility slightly, depending on the concentrations mixed;
there can be a difference of over 50% (Table 4.3). Meanwhile, mixing iron dextran and iron(III)
chloride did not result in large deviations from the predicted susceptibility. Since we cannot
estimate the susceptibility in a controlled phantom environment, we must take caution when
comparing phantom data to human data. The iron concentrations that provide a specific
susceptibility in phantoms may not translate precisely to human data due to the difference in
tissue background.
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There are several limitations to this phantom study. First, the ratio of Fe2+ to Fe3+ in the human
hemoglobin samples could not be controlled since it was in contact with room air in its
packaging. Hemosiderin, the primary component of chronic hemorrhage was also not available
for testing. As previously discussed, the phantoms also are not a perfect substitute for human
tissue. We did not perform T1- or T2-mapping to determine how biosimilar the background
material was to brain tissue because we were primarily focused on modeling the T2* effects
found in hemorrhagic lesions.
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Chapter 5

5

5.1

Lesion Differentiation in Human Subjects with DECT and PS-MRI

Introduction

The correct characterization of intracranial low-density calcification and hemorrhage is a
challenging clinical problem that may have a direct impact on both diagnosis and clinical
management. We have identified two promising methods for distinguishing between these two
lesion categories: dual-energy CT (DECT) and quantitative susceptibility mapping (QSM).
DECT provides material differentiation through interrogation of the lesion by more than one xray spectra, in effect allowing the photoelectric effect and Compton scattering components of
attenuation to be determined. In comparison, the goal of QSM is to map the magnetic
susceptibility of tissue, for which diamagnetic calcium should return a negative susceptibility
while paramagnetic blood products lead to a positive susceptibility measurement. There have
been multiple studies in the literature regarding the differentiation of calcific and hemorrhagic
lesions in the brain (45, 137, 205, 206). However, there have been no studies to date
comparing these two complimentary modalities, nor have there been prospective clinical trials
of these new technologies. Both modalities have the potential to provide uniquely valuable
clinical information about these lesion types through two independent physical mechanisms:
magnetic susceptibility and x-ray attenuation properties. This chapter details a prospective
imaging trial in patients with brain lesions with the goal of identifying and characterizing
intracranial calcifications and hemorrhage in vivo.

5.2

Methods

5.2.1 Study Population
Up to 100 evaluable adult patients with lesions at least 1.0 cm in diameter indicated by foci of
susceptibility on conventional MR or lesions on routine CT were to be recruited into this trial,
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which was approved by the local Institutional Review Board. Subjects in the subset of the data
presented here entered the trial between October 2016 and February 2018.
Table 5.1: Study inclusion and exclusion criteria. Additional contraindications to MRI can
be found in Appendix 1
Inclusion Criteria

Exclusion Criteria

> 18 years of age

Failure to obtain consent

Foci of susceptibility ≥ 1 cm in size on T2*-

Contraindications to MRI

weighted GRE of the brain



Incompatible implanted device

OR



Claustrophobia

SECT lesion ≥ 1 cm in size and < 100 HU

Positive urine pregnancy test

5.2.2 Study Design
Study subjects were recruited from the set of MD Anderson patients undergoing T2*-weighted
GRE imaging as part of routine clinical MRI of the brain. These studies were imported into
screening software developed in house (see Appendix 2) on a daily basis. The software
enabled the user to cycle through all patient datasets sequentially; trained study personnel
marked images with a likely focus of susceptibility greater than 1 cm in at least one dimension
for a neuroradiologist to review at a later time. Patients also could be referred to the study by a
radiologist or their physician if they had a lesion of unknown composition greater than 1 cm in
any dimension and a measured attenuation of under 100 HU on clinical SECT. This size
threshold was chosen to qualify a patient for the trial because DECT analysis becomes less
accurate as lesion size decreases below 1.0 cm, based on a preliminary study performed by
our group (136). That study showed that for lesions with attenuations below 100 HU,
differentiation of calcific and hemorrhagic lesions was not possible when the lesion size
reached 0.5 cm in diameter; however, due to the limitations of the phantom design, we were
unable to define a precise size threshold under which DECT did not provide additional
information over SECT. Because lesions presenting with susceptibility on clinical T2*-weighted
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GRE often appear larger than they would on pulse sequences that are less vulnerable to
susceptibility artifacts, such as fast spin echo sequences, using 1 cm as a threshold on GRE
images allowed for the inclusion of some slightly smaller lesions as measured by CT to qualify
patients for the study. Furthermore, while a patient was required to have at least one lesion
over 1.0 cm in diameter on T2*-weighted GRE, many patients had additional lesions present
that were smaller that were also available for analysis.

From this subset of patients initially screened into the trial, the study radiologist (Dr. Dawid
Schellingerhout) selected subjects with lesions of unknown composition for potential
recruitment by a research nurse. The research nurses excluded patients if they declined to
participate, were deceased or had entered hospice care, had an implanted device incompatible
with 3.0 T MRI, had the lesion of interest resected, were no longer receiving care at our
institution, or if they required an interpreter (due to lack of access at our small research center).
All others were recruited to the study, with informed consent documented.

After screening and study enrollment by research staff, all patients (n = 52, 29 male and 23
female, aged 25 – 78 years [mean age ± standard deviation: 59.1 ± 12.8 years]) underwent
non-contrast SECT, non-contrast DECT, and non-contrast MRI at the MD Anderson Center for
Advanced Biomedical Imaging. Since many of the patients were recruited following screening
MR, we expected that some lesions would have a SECT attenuation value greater than 100
HU. Therefore, following image registration of the PS-MRI and CT examinations, the analysis
was separated into two arms (Figure 5.1):
1) Lesions with SECT attenuation ≥ 100 HU, for which SECT can be considered a gold
standard for the diagnosis of calcification, and
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2) Lesions with SECT attenuation < 100 HU, where no existing gold standard is
available, and for which analysis would be informed by the phantom analysis and
concordance/discordance of the QSM and DECT analysis.

Figure 5.1: Study flowchart showing flow from screening to study enrollment and imaging,
to the analysis of individual lesions in subsets of known calcifications and unclassified
lesions.
5.2.3 SECT and DECT Imaging
SECT and DECT were acquired on a fast kVp-switching capable system (Discovery HD750
CT; General Electric Healthcare, Waukesha, WI). The SECT scan was identical to the clinical
routine brain CT performed at our institution; the DECT protocol was informed by the work of
Nute et al. (136), which indicated that accuracy improved with higher rotation times and
CTDIvol. These protocols are displayed in Table 5.2. Multiple image sets were reconstructed
from the DECT exam. Material images with a calcium/water basis pair were generated (136).
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Table 5.2: Study SECT and DECT imaging protocols. The scan range, image thickness,
beam width, and field-of-view (FOV) were held constant between the two examinations.
Technique Parameter

SECT

DECT

Scan Type

Helical

Helical GSI

Area

Maxillary Teeth to Vertex

Maxillary Teeth to Vertex

kVp

120

80/140

mA

220

600

Rotation Time (s)

0.8s

0.9

Pitch

0.531

0.531

CTDIvol (mGy)

65.2

132.6

Image Thickness (mm)

0.625

0.625

Interval (mm)

0.625

0.625

20

20

Head

Head

250

250

Beam Width (mm)
Scan FOV
Display FOV (mm)

5.2.4 MR Imaging
Imaging was performed on a 3.0-T MRI system (MR 750, General Electric Healthcare) with an
8-channel head coil. A three-dimensional (3D) T1-weighted ultrafast gradient echo with
magnetization preparation (IR-FSPGR) was acquired for anatomical reference. A T2*-weighted
GRE was acquired for comparison of the signal level for comparison to the clinical MR. A 3D
susceptibility-weighted angiography (SWAN) sequence was acquired to examine the
background phase—which is automatically reconstructed—in each material, and a 3D multiecho fast gradient recalled echo (MFGRE) was acquired to assess signal changes with
increasing echo time (TE) and calculate QSM images. Scan parameters are located in Table
5.3
5.2.5 Phase-Sensitive MRI Post-Processing
The first echo of the MFGRE (TE approximately 4.5 ms) was loaded into 3D Slicer to create a
mask of the brain for Quantitative Susceptibility Mapping (QSM). The cerebrum, brain stem,
and cerebellum were manually masked, and the resulting logical image set was loaded into
96

Matlab (R2016a; MathWorks, Natick, MA) for QSM processing along with the real and
imaginary DICOM images from the MFGRE. QSM processing was performed using
Morphology-Enabled Dipole Inversion, which included phase unwrapping and background
phase removal using Projection onto Dipole Fields as preparatory steps (167, 234, 235). QSM
reconstruction took approximately one hour per iteration, with an average of six iterations on a
2.8 GHz Dual-Core Opteron Processor 8220 (Advanced Micro Devices, Santa Clara, CA) with
up to 128 GB of RAM available.
Table 5.3: MRI acquisition details for the patient trial, including repetition time (TR),
inversion time (TI), receive bandwidth (BW), field-of-view (FOV), acquisition matrix
Sequence

IR-FSPGR

T2*-weighted GRE

3D SWAN

3D MFGRE

# of Echo Times

1

1

6

12

TE (ms) [min, max]
2.1
15
23.3a
[4.7, 61.4]
TR (ms)
5.7
600
37.6
65.2
TI (ms)
400
Flip Angle
20°
20°
15°
20°
BW (kHz)
128
128
128
128
FOV (mm)
220
220
220
220
Phase FOV (% of FOV)
80
75
80
80
Matrix
256 x 256
256 x 256
320 x 224
416 x 320
Slice Thickness (mm)
1.4
5
1.4
1.4
Scan Time
4:27
2:00
2:49
6:46
a
SWAN provides images that are a weighted average of the six echoes. The average TE is
listed here.
5.2.6 Image Registration and Segmentation
Image registration and segmentation were performed in 3D Slicer (Version 4.6, Brigham and
Women’s Hospital, Boston, MA). All images were co-registered to the axial 3D T1-weighted
MRI (due to its geometric accuracy) with an affine transformation (236). Foci of susceptibility
were segmented on the first echo of the registered MFGRE (TE = 4.5 ms) to minimize blooming
of the lesion. Known calcifications were identified on the registered SECT as those lesions with
a mean attenuation greater than 100 HU, including physiologic calcifications in the pineal
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gland, choroid plexus, and falx. Suspected calcifications less than 100 HU were also identified
on the CT. A circular ROI was placed in the lateral ventricle as a control on the QSM images.

The ROI locations defined in 3D Slicer were saved and loaded into Matlab. Automated
processing in Matlab was utilized to apply the ROIs to each registered image set for a given
patient. For each ROI location and image type, the software saved the voxel data, calculated
the ROI mean and standard deviation, and median.
5.2.7 Reference Standard
The current clinical standard for classification of brain lesions as either hemorrhagic or calcific
is to assign all lesions with SECT attenuation greater than 100 HU as calcification.
Subsequently, both clinical and imaging features are used to make a probabilistic determination
of hemorrhage or calcification for lesions under the 100 HU threshold. The following examples
represent a brief, non-comprehensive demonstration of the clinical thinking that was used to
define this clinical reference standard:


Lesions that exhibited susceptibility on T2*-weighted GRE but were located in the pineal
gland, choroid plexus, or dura mater were assigned as calcification if there were no
other signs of bleeding on CT or MRI (237).



For lesions in the brain parenchyma, the lesion was labeled as hemorrhage if it was isoor hypo-intense on CT and exhibited significant blooming on T2*-weighted GRE
compared to the 3D T1-weighted IR-FSPGR sequence or met the other criteria defined
in Table 2.2.



For lesions suspected of hemorrhage with hyperintensity on CT, the clinical history was
examined to see if hemorrhage was clinically likely. For example, a history of known
hemorrhagic metastases or recent treatment of a lesion with stereotactic radiotherapy
were presumed to be hemorrhagic.
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This clinical reference standard was applied to all lesions by our study neuroradiologist (DS, 18
years experience), making use of imaging data available from the study and prior routine brain
studies, as well as clinical information available from the electronic medical record (such as a
history of recent surgery or radiation). Clinical MR brain imaging at our institution included, but
was not limited to, T1-weighted, T2-weighted, and T2 FLAIR pulse sequences. CT imaging
prior to the study exam was not available for all patients.

5.2.8 SECT Analysis
Lesion data were collected on the SECT. Histogram analysis was performed to assess the
current clinical ability of CT to differentiate between calcific and hemorrhagic lesions. Receiver
Operating Characteristic (ROC) analysis was performed utilizing the clinically accepted
threshold of 100 HU to differentiate between hemorrhage and calcification.
5.2.9 DECT Analysis
Lesion data were collected for a calcium/water two material decomposition. ROC analysis was
performed on the water(calcium) and calcium(water) data individually compared to the
reference standard. Logistic regression with 5-fold cross validation was performed in Matlab on
the water(calcium) and calcium(water) with the initial clinical reference standard used as the
classification metric to determine the probability that specific calcium and water measurements
were indicative of either hemorrhage or calcification. The logistic fit equation is given by the
equation below,
𝑝(𝑥𝑤 , 𝑥𝑐 )
Equation 5.1
ln (
) = 𝛽0 + 𝛽𝑤 𝑥𝑤 + 𝛽𝑐 𝑥𝑐
1 − 𝑝(𝑥𝑤 , 𝑥𝑐 )
where 𝑥𝑤 represents the water(calcium) means and 𝑥𝑐 represents the calcium(water) means.
𝛽0 , 𝛽𝑤 , and 𝛽𝑐 are the fitted coefficients for the logit model resulting from the logistic regression
(238). Receiver operating characteristic (ROC) analysis was performed to determine the
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sensitivity, specificity, and area under the ROC curve (AUC) for the DECT diagnostic task. The
optimal cutoff for the ROC analysis was determined using the Youden index (J) (239):
𝐽 = max(𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 + 𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 − 1)

Equation 5.2

Diagnostic accuracy was calculated relative to the reference standard.
5.2.10 QSM Analysis
Measurements were made in the cerebrospinal fluid (CSF) of each patient, and the mean
susceptibility recorded within each patient because CSF is primarily water, which has a known
susceptibility (𝜒 = -9.05 ppm) (204). A Shapiro-Wilk test was performed on the CSF
measurements to determine if the distribution of the measured susceptibility was gaussian. The
QSM of a lesion was considered to be positive for hemorrhage if the measured susceptibility
was greater than the group sample mean of the CSF measurements across patients, the lesion
was considered hemorrhagic. If the lesion’s susceptibility was lower than that of the group CSF
sample mean, the lesion was considered to be calcific. ROC analysis was also performed to
assess the performance of QSM for the differentiation of calcific and hemorrhagic lesions with
an optimal cutoff at the Youden index (Equation 5.2). Diagnostic accuracy for each modality will
be considered relative to the reference standard.
5.2.11 Statistical Analysis
McNemar’s test was used to compare the binary DECT and QSM classifications—calcification
or hemorrhage—for all lesions overall and within each subgroup (SECT < 100 HU and SECT ≥
100 HU) to test for consistency in classification between the two modalities (240). The level of
the concordance was assessed using Cohen’s Kappa statistic (241).

The marginal utility of both DECT and QSM will be determined by comparing the ROC analysis
of the individual modalities to the ROC characteristics of SECT alone (242, 243). The optimal
thresholds for each modality were chosen from ROC analysis of the whole dataset.
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5.3

Results

5.3.1 Study Population
Screening data is shown in Figure 5.2, including the total number of unique patients viewed by
study personnel, the number of patients having a preliminary lesion marked, and the number of
patients approved by the study’s neuroradiologist for recruitment. Of the 754 patients deemed
eligible for the study based on clinical T2*-weighted GRE imaging, a total of 702 were either
excluded, declined to participate, or were unable to be contacted. A total of 52 patients were
scanned from October 2016 to February 2018. Two patients were excluded from this analysis
due to image artifacts due to motion in the MFGRE pulse sequence used to generate the QSM
images. Within this population, there were a total of 328 total foci of susceptibility identified; the
initial clinical classification used as a reference standard indicated 189 calcifications and 139
hemorrhagic lesions in total.

Figure 5.2: Subject accrual flow chart
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5.3.2 SECT Analysis
There were a total of 179 lesions with a SECT attenuation greater than or equal to 100 HU. A
histogram with kernel density estimates demonstrates the distribution of SECT HU for the
hemorrhage and calcification groups as defined by the reference standard (Figure 5.3).

Figure 5.3: SECT values for lesions classified as hemorrhage and calcification by the
reference standard. The dotted black line marks the current established threshold for
differentiating between calcification and hemorrhage on SECT (100 HU). Note that
applying this threshold rigidly would misclassify multiple calcific lesions as hemorrhagic,
based on initial clinical classification.

While the kernel density estimates in Figure 5.3 overlap, the hemorrhage with the highest
attenuation measured 53.7 HU; the calcification with the lowest attenuation measured 67.5 HU.
As a result, any threshold between 53.7 and 67.5 HU would effectively separate the
hemorrhage and calcification present in this dataset. The ROC analysis returned an optimal
threshold of 67.5 HU, at which the accuracy, sensitivity, and specificity were all 100%.
However, using a threshold of 100 HU, which is currently utilized clinically, has an accuracy of
95.1%, sensitivity of 100%, and specificity of 91.8%
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5.3.3 DECT Analysis
ROC analyses of the calcium(water) and water(calcium) data returned optimal
thresholds of 11.76 mg Ca/mL and 1030.7 mg H2O/mL, respectively. The calcium(water)
images provided better discrimination between the hemorrhagic and calcific lesions than the
water(calcium) images (Figure 5.4). Combining the data from both DECT image types, the
logistic regression of the calcium(water) and water(calcium) data returned the linear
combination coefficients found in Table 5.4. The calcium(water) was the only statistically
significant parameter in the fit. The calcium density is the primary predictor, which can be seen
visually in Figure 5.6a, in which a line that represents the optimal threshold between the calcific
or hemorrhagic lesions has been superimposed on a scatter plot. The threshold that optimized
the Youden index (Equation 5.2) for the logit model was a linear metric (𝛽0 + 𝛽𝑤 𝑥𝑤 + 𝛽𝑐 𝑥𝑐 ) of 2.68 (Figure 5.6b). The mean and standard deviation for each lesion type as defined in the
model are in Table 5.5 for SECT, water(calcium), and calcium(water) image types, and the 2 x
2 classification matrices are in Figure 5.5. The overall accuracy of this model was 99.7%
(327/328) amongst the entire dataset (Figure 5.5, Table 5.10), 100% (179/179) amongst SECTproven calcifications, and 99.3% (148/149) amongst lesions with SECT < 100 HU. The
sensitivity and specificity in the full dataset were 99.3% (134/135) and 100.0% (193/193).
Table 5.4: DECT logistic regression. The equation for the fit is given in Equation 5.1. A pvalue of less than 0.05 represents the statistical significance of the parameter within the
model (indicated by *).
Coefficient t Statistic p-value
Intercept (𝛽0 ) -122.900

-1.77

0.077

Water(Calcium) (𝛽𝑤 ) 0.112

1.66

0.096

Calcium(Water) (𝛽𝑐 ) 0.549

4.23

< 0.001*
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Figure 5.4: ROC curves for Water(Calcium) and Calcium(Water) data compared to the ROC
curve for SECT with a threshold of 100 HU.

Table 5.5: Mean SECT, water(calcium), and calcium(water) measurements for lesions
classified as hemorrhage and calcification in the DECT-based logistic regression.
DECT Classification Hemorrhage (n = 133) Calcification (n = 195)
Mean
SECT (HU) 34.9
Water(Calcium) (mg/mL) 1021.9
Calcium(Water) (mg/mL)

5.2

Standard
Deviation
8.3

Mean
177.6

Standard
Deviation
86.1

7.0

1048.7

16.7

2.1

44.7

24.4
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Figure 5.5: a) Classification matrices for the DECT-based logistic model compared to the
reference standard and b) the ROC curve for the DECT and SECT classification schemes.

Figure 5.6: DECT water(calcium) and calcium(water) data classified by the reference
standard. a) A scatter plot of the water(calcium) and calcium(water) means for all 328
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lesions. The dotted black line represents the optimal threshold between calcification and
hemorrhage in the logistic model, where a linear combination of the water and calcium
data is equal to -2.675. b) The logistic regression compared to the reference standard.

5.3.4 QSM Analysis
Across the 50 patients studied, the mean susceptibility of CSF was 27.5 ± 10.1 ppb (Figure
5.7), and normality was confirmed with a Shapiro-Wilk test (p = 0.71). Of the 328 susceptibility
lesions identified, by QSM, 192 lesions were classified as calcifications (-109 ± 129 ppb) and
136 as hemorrhage (730 +/- 457 ppb) using the mean QSM of CSF as a threshold, for a total
accuracy of 98.5% (323/328). However, a threshold set at 37.6 ppb (CSF mean plus one
standard deviation) satisfies the Youden index (Figure 5.8). The means and standard
deviations of the SECT and QSM for each classification are in Table 5.6, and scatterplots are
showing the relationship between SECT and susceptibility are shown in Figure 5.9. Compared
to the reference standard, the diagnostic accuracy using the 37.6 ppb threshold was 99.4%
(326/328) in the whole dataset, 100% (149/149) in lesions with SECT < 100 HU, and 98.9%
(177/179) in lesions with SECT ≥ 100 HU. The sensitivity and specificity were 98.5% (133/135)
and 100% (193/193) in the whole dataset, 100% (133/135) and 100% (14/14) for lesions under
100 HU, and specificity was 100% (179/179) in lesions greater than 100 HU. In this final
category, sensitivity could not be calculated because there were no cases positive for
hemorrhage.
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Figure 5.7: Histogram of the CSF susceptbility measurements for 50 patients with a
Gaussian fit (left). A quantile-quantile plot is shown on the right to display the deviation
of individual measurements from the displayed normal distribution (right). A Shapiro-Wilk
test did not reject the null hypothesis that the distribution was Gaussian (p = 0.71).
Table 5.6: Mean SECT and QSM measurements for lesions classified as hemorrhage and
calcification based on a threshold of 37.6 ppb.
Hemorrhage (n = 135) Calcification (n = 193)
Mean

Mean

SECT (HU) 36.8

Standard
Deviation
18.5

177.7

Standard
Deviation
86.4

QSM (ppb) 741.8

445.8

-117.6

97.9
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Figure 5.8: a) Classification matrices for the QSM-based logistic model compared to the
reference standard and b) the ROC curve for the QSM and SECT classification schemes.
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Figure 5.9: a) Mean QSM for each lesion versus the SECT attenuation in HU. Note that two
lesions measure both over 100 HU and well above a susceptibility of 37.6 ppb. These two
lesions are known as outliers where calcification is present adjacent to a vein or
hemorrhagic lesion. b) Histograms of the QSM mean for calcifications and hemorrhages
with kernel density estimates of the distributions. The optimal threshold of 37.6 ppb is
shown in yellow in both plots.
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Figure 5.10: A 48-year old female patient with a history of right frontal craniotomy and a
lobular mass consistent with cavernoma presenting as a large focus of susceptibility on
the MFGRE (TE = 14.5 ms) (a). The SECT (b) demonstrates a densely calcified region
within the lesion (red outline) with HU greater than 100. (c) QSM of the lesion shows high
magnetic susceptibility thoughout the lesion with regions of apparent aliased signal.
The calcification does not present with the expected negative susceptibility.

Figure 5.11: A 73-year old female patient with a history of metastatic melanoma with
Gamma Knife therapy. (a) The globus pallidus shows mineralization consistent with
aging that causes low signal on the MFGRE (TE = 14.5 ms). (b) SECT shows a small
calcification (green outline) within the globus pallidus with attenuation over 100 HU. (c)
QSM shows consistently high signal in the globus pallidus despite the presence of
calcification, but other calcific lesions (yellow arrows) demonstrate the expected
negative susceptibility.
5.3.5 Statistical Analysis
The 2 x 2 classification matrices comparing the DECT and QSM classifications for the
whole dataset, lesions with SECT < 100 HU, and lesions with SECT ≥ 100 HU are found in
Table 5.7 - Table 5.9. For each of these classifications respectively, McNemar’s test returned p
= 1.000, p = 1.000, and p = 0.500, indicating that QSM and DECT were concordant. 𝜅 was
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equal to 0.981 and 0.964 for the whole dataset and those lesions under 100 HU; 𝜅 could not be
computed for lesions over 100 HU because DECT did not indicate the presence of any
hemorrhagic lesions. Therefore, concordance between the two modalities was very high, and
we can assume that the lesions under 100 HU for which QSM and DECT are in agreement
(133 hemorrhagic lesions, 15 calcific lesions) are accurately classified. Accuracy, sensitivity,
specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the
ROC curve (AUC) are tabulated in Table 5.10.

Table 5.7: Classification matrix for the QSM classifications of all lesions versus the
DECT classifications for all lesions

DECT

Whole Dataset

QSM
Hemorrhage Calcification

Hemorrhage

133

1

Calcification

2

192

Table 5.8: Classification matrix for the QSM classifications of all lesions versus the
DECT classifications for lesions with SECT greater than 100 HU.

DECT

SECT > 100 HU

QSM
Hemorrhage Calcification

Hemorrhage

0

0

Calcification

2

177

Table 5.9: Classification matrix for the QSM classifications of all lesions versus the
DECT classifications for lesions with SECT less than 100 HU.

DECT

SECT < 100 HU

QSM
Hemorrhage Calcification

Hemorrhage

133

1

Calcification

0

15
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Table 5.10: Comparison of the ROC analysis for SECT (threshold = 100 HU), DECT, and
QSM ROC analyses. Values were calculated for water(calcium) and calcium(water) images
in the whole dataset. Dashes represent values that could not be calculated due to division
by zero. The AUC for the SECT data was calculated assuming a threshold of 100 HU.
Data
Subset

Whole
Dataset

SECT <
100 HU
SECT ≥
100 HU

5.4

Classification Method

Accuracy Sensitivity Specificity PPV NPV

AUC

SECT (HU)

95.1

100

91.8

89.3

100

0.976

Water(Calcium)

90.9

92.5

89.7

92.5

89.7 0.970

Calcium(Water)

99.3

98.5

99.0

98.5

100

DECT (Logistic Model)

99.7

99.3

100

100

99.5 0.998

QSM (ppb)

99.4

100

98.5

100

99.0 0.991

SECT (HU)

89.3

100

0

89.3

-

DECT (Logistic Model)

99.3

99.3

100

100

93.8

QSM (ppb)

100

100

100

100

100

SECT (HU)

100

-

100

-

100

DECT (Logistic Model)

100

-

100

-

100

QSM (ppb)

98.9

-

98.9

0

100

0.997

Discussion

This study evaluated both DECT and QSM for the identification of calcification and hemorrhage
in vivo. Our initial clinical reference standard was based on a radiologist’s interpretation of the
lesion based on the available prior clinical MRI imaging (including T2*-weighted GRE and T1and T2-weighted imaging) and the study exams. This standard was found to be highly
concordant with the subsequent quantitative analyses. It is of paramount importance to the
interpretation of the results presented here that the study was performed in an outpatient
population with chronic lesions. Patients presenting with acute symptomatic lesions in an
emergent setting frequently have hemorrhagic lesions of higher attenuation, and we would
anticipate that we would see additional overlap in the SECT attenuation of the calcific and
hemorrhagic lesions if these patients were included in the trial. As the overlap in attenuation
would increase, we would expect that the results, particularly for the DECT analysis, would
result in worse differentiation.
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We confirmed the efficacy of QSM for the accurate differentiation of diamagnetic and
paramagnetic materials (45, 205, 206). DECT calcium(water) and the DECT logistic regression
both had higher accuracy compared to SECT with a 100 HU threshold for this lesion
classification. As DECT becomes increasingly available clinically, it may provide additional
avenues for the diagnosis of hemorrhage, particularly for patients in emergent settings or those
with contraindications to MRI.

There are inherent difficulties in determining the reference standard for these lesions because
there is no true gold standard under 100 HU on SECT. In cases where no true gold standard
exists, it has been established within the statistical literature that agreement statistics between
two diagnostic tests provides valuable diagnostic information (244, 245). Because we were
differentiating between two diagnostic classes, calcification and hemorrhage, we utilized the
methodology developed by McNemar (240). In a two by two contingency table, such as Table
5.7, the concordant results in which both tests agree are ignored in McNemar’s test, and
instead the null hypothesis is that the probability of discordant measurements that are positive
by test 1 and negative on test 2 is equal to those that are positive on test 2 and negative on test
1 (240). Therefore, if the null hypothesis is rejected, the two tests provide different results. In
this case, McNemar’s test did not reach statistical significance when testing QSM against
DECT for the differentiation of chronic hemorrhage and calcification, so we could assume that a
lesion that had the same classification by both imaging modalities being tested was an
accurate diagnosis.

With access to follow-up imaging for nearly all patients, we were able to establish a clinical
reference standard using both CT and MRI. However, this was still based on a conventional
understanding of the properties of calcification and hemorrhage on conventional imaging; we
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have shown in this work that intracranial calcification can have SECT attenuation values under
100 HU (Figure 5.3). We also considered the results of the DECT and QSM to be accurate if
the two modalities were concordant. Prior studies had only diagnosed calcification if the lesion
was greater than 100 HU or they had pathologic proof (45, 205, 206). Chen et al. found
Morphology-Enabled Dipole Inversion (MEDI) QSM, which was also utilized in this study, to
have a sensitivity of 89.5% and specificity of 94.5% for detection of hemorrhage and
calcification (45). Our study focused on a slightly different task, in which segmentation was
performed on the MFGRE and SECT images. However, by utilizing foci of susceptibility that
represented known physiologic calcifications, we were able to demonstrate very high sensitivity
and specificity for QSM at 99.4% and 98.5%, respectively, within the whole dataset.

The work of Nute et al. was the first to utilize DECT imaging to differentiate between
intracranial calcification and hemorrhage by utilizing several phantom studies (135, 136). We
utilized the protocol recommended in said work and a calcium/water material decomposition
(136). Despite this study being developed as a corollary of that phantom work, there were
several key differences as we translated this work from phantoms into humans. First, we did
not investigate the use of multiple image thickness values. It is likely that there would be
significant image quality improvements in the DECT images if a thicker image were used, at the
expense of losing spatial resolution and being unable to analyze smaller lesions. The second
was that we found that the 68 keV data, which formed the z-axis in a 3D feature space, was
highly correlated with the calcium(water) data from the patient lesions and could be eliminated
from the differentiation algorithm (136). While the SECT attenuation of each lesion was still
used as a reference point for reporting purposes, this simplifies the analysis in the long term,
which could encourage clinical use.
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In comparison to another DECT study differentiating calcific and hemorrhagic lesions, our study
had a larger proportion of chronic hemorrhagic lesions since the clinical imaging was
conducted on a purely outpatient basis, an was not performed in an emergency room or
inpatient setting (137). Additionally, ROC analysis of SECT data showed that an optimal
threshold could be found without using DECT to differentiate between chronic hemorrhage and
calcification based on density alone. There was a total of 53 lesions that had a mean SECT HU
between 40 and 100 HU, and we estimate that 16 of them were calcific based on concordance
between the DECT and QSM. Of those 53 lesions within an HU range expected of acute or
sub-acute hemorrhage (3, 26, 246), 31 did not have a SECT attenuation higher than 50 HU.
The primary disadvantage of this is that chronic hemorrhagic lesions may not be readily visible
relative to the brain parenchyma on DECT because they have similar attenuation levels as gray
and white matter. Therefore, DECT may be of limited utility for patients that cannot undergo
conventional T2*-weighted GRE MRI to identify regions where susceptibility is present.
However, results of a previous phantom study from our groups demonstrated that fast-kVp
switching CT was able to differentiate between calcific and hemorrhagic lesions of comparable
SECT HU above 50 HU (136). The inclusion of acute hemorrhage in future trials will allow us to
confirm the results of the phantom study.

Two patients had to be excluded from the study due to motion artifacts that corrupted the
MFGRE data used for QSM processing. The pulse sequence used in this study was comprised
of 12 echo times, which increased the scan time compared to the SWAN sequence that was
utilized in our phantom studies (Chapter 4). The MFGRE sequence is also a three-dimensional
pulse sequence, which is inherently more susceptible to motion artifacts throughout the entire
scan field of view compared to two-dimensional sequences. For clinical implementation, it
would be advantageous to limit the acquisition time in order to lower the chance of nondiagnostic images that could not undergo additional processing. There are many possible
115

avenues to consider in order to achieve this goal. The number echoes could be lowered to six
or eight, and the spatial resolution could be reduced compared to this research sequence.
Overall, this indicates that DECT, with acquisition times under 30 seconds, may be a valuable
alternative for differentiating calcific and hemorrhagic lesions in patients that are unable to
remain still for long periods of time due to their medical condition during an MR exam.

QSM remains time intensive at approximately one hour per iteration for an average of six
iterations. This time could be lowered significantly by utilizing servers with higher processer
speeds than those available for use in this study. Decreasing the spatial resolution of the
MFGRE pulse sequence, particularly the number of images per slab, would also reduce the
computation time required for the QSM. Except for two calcifications which were adjacent to
known hemorrhage or venous structures, QSM proved to be highly sensitive in identifying both
hemorrhage and calcification. The QSM processing in the MEDI algorithm includes the option
for using a spherical mean value to help acquire the true susceptibility in brain parenchyma.
This can minimize the appearance of subtle artifacts that may remain after MEDI processing by
averaging data in a sphere surrounding a specific voxel but may cause additional volume
averaging near anatomical edges. While lesion edges were generally avoided when placing
ROIs in this study, it may have contributed to the errors seen near chronic hemorrhage with
very high susceptibility (Figure 5.10, Figure 5.11). The lesions that were misclassified were
both small calcifications surrounded by high positive susceptibility regions. Because the
magnitude of the magnetic susceptibility in iron-based lesions (including mineralization in deep
gray matter) is much higher than that of calcification, any averaging present may result in small
calcific lesions being masked by adjacent iron deposition. Adjusting the spherical mean value
diameter setting may be of interest to clinicians as this method gains wider acceptance in the
clinic in order to optimize the post processing for a given application to balance the
visualization of small calcifications and minimization of artifacts.
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There were several other limitations in this study. The first is that screening was performed
nearly entirely on T2*-weighted GRE MRI, which is highly sensitive to chronic hemorrhage.
Because most patients entered into the study did not have a head CT available for comparison,
there was no way to guarantee that lesions were a) visible on CT and b) within the desired 40 –
100 HU range. Because the lesions were not necessarily visualized on SECT or DECT,
segmentation of the lesions of interest (outside known calcifications) was performed on the
MFGRE. Some disadvantages of using the MFGRE for this purpose include lower spatial
resolution than the SECT and the potential for blooming artifact. Blooming, in particular, would
cause an ROI to be larger than the actual lesion and could degrade the DECT results by
including normal brain tissue surrounding the lesion within the volume of interest. The second
limitation is that the study was performed at an ambulatory clinical research center rather than
in an emergent or inpatient setting. The study location further skewed the study towards cases
of chronic hemorrhage because the majority of patients with acute hemorrhage were too ill to
undergo the imaging required for the study. This ultimately meant that ROC analysis was able
to find a SECT threshold that had slightly higher accuracy than the DECT in this dataset. We
know from clinical experiences at other institutions that this would not be the case were acute
hemorrhage more prevalent in the study (137).

Future work will include continued patient accrual through September 2018 or until 100 patients
have been scanned. We plan on investigating whether DECT monoenergetic images may
further assist in the differentiation of hemorrhage and calcification. Additionally, we have a
multi-modality dataset that can also be used to determine the optimal monoenergetic energy for
comparisons to SECT, investigate the extent of blooming artifact compared to the quantitative
susceptibility of lesions, and further quantify the magnetic susceptibility of normal tissues within
the brain. This extensive dataset may enable further comparisons in this dataset to DECT
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material decompositions utilizing iron as in the material decomposition. In addition, this work
justifies a future clinical trial which would investigate the differentiation of acute hemorrhage
and calcifications in an emergent setting.
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Chapter 6

6

6.1

Conclusions

Summary of Findings

In this dissertation, we explored the application of DECT and Phase-Sensitive MRI (PS-MRI)
techniques for the classification of intracranial calcific and hemorrhagic lesions. On
conventional T2*-weighted MRI, both these lesion types are indicated by the presence of dark
spots in the image that result from the presence of a material with a magnetic susceptibility
different from the surrounding normal tissue. Calcium is diamagnetic while most iron-based
compounds are paramagnetic, so utilizing the MRI phase in susceptibility-weighted pulse
sequences is a promising technique for differentiating the two lesion types.

In Chapter 3, we validated phantom materials that modeled the signal properties of calcific and
hemorrhagic lesions on a multi-echo GRE pulse sequence. T2*, the time it takes for a
material’s spins to dephase when field inhomogeneities are present, was a quantity that we
could use to compare our phantom materials to the biological T2* values for calcification and
hemorrhage in the literature. We investigated a total of seven materials (two calcium-based and
five iron-based) for use in an MR phantom. Four materials were chosen for use in the final two
phantoms based on their T2* values: hydroxyapatite, iron dextran, iron(III) chloride, and human
lyophilized hemoglobin powder. Our lab developed hydroxyapatite agarose gels for use in a
DECT phantom (135), but few studies were available in the literature which utilized calciumbased MRI phantoms (208, 215, 247). Because of this work, we determined that powdered
hydroxyapatite embedded in agarose does adequately model the T2* decay properties of lowdensity intracranial calcifications. Similarly, we determined that three iron-based compounds—
iron dextran, iron(III) chloride, and human hemoglobin—had T2* values comparable to that of
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hemorrhagic lesions and iron-laden deep gray matter, with T2* between approximately 5 and
35 ms (209-211).

After demonstrating that we could model the appearance of hemorrhage and calcification on
T2*-weighted GRE magnitude images in phantoms, we began to assess the feasibility of
differentiating between the two iron- and calcium-based models with PS-MRI (Chapter 4). The
phantoms developed in Chapter 3 provided a simple physics model for testing different PS-MRI
methods. The first method tested in phantoms was the automatically-processed filtered phase
image from the SWAN pulse sequence. We found that these phase images did not have
sufficient phase unwrapping, and, as a result, the phase did not correlate well with increasing
concentration of either diamagnetic or paramagnetic materials (Figure 4.3). The second
method tested was Projection onto Dipole Fields (PDF), which results in a background
subtracted phase image. These images were of higher quality than the SWAN phase images,
and we could visually discriminate between calcification and hemorrhage. There was a high
correlation between the phase and all materials except iron(III) chloride. Additionally, there was
some shading around samples with high positive susceptibility that would be a confounder for
clinical diagnosis of calcification and hemorrhage (Figure 4.5d). Finally, the PDF image was
used as an input for Quantitative Susceptibility Mapping (QSM) in which the background
subtracted phase (which provides a map of the local magnetic field) was used to solve an
inverse problem that returns the distribution of magnetic susceptibility within the phantom. The
QSM processing was able to eliminate some of the errors in the iron(III) chloride samples found
in the PDF phase images. The improvement in the QSM of the iron(III) chloride over the PDF is
likely due in part to the additional spherical mean value averaging that helps to arrive at the
true susceptibility within a reasonably uniform region. Additionally, the shading surrounding
several lesion models in the PDF images was resolved in the QSM. Overall, QSM had the
highest correlation between material concentration and susceptibility, and the images are easily
120

interpretable—diamagnetic materials returned negative susceptibility while paramagnetic
materials had a positive susceptibility.

Given the results of Chapter 4, we focused on the ability of SECT, DECT, and QSM to
differentiate between calcific and hemorrhagic lesions in vivo (Chapter 5). The human trial
accrued a total of 52 patients with 328 lesions. Of those lesions, 179 were classified as
calcification definitively by SECT (HU ≥ 100). Overall, a clinically-derived reference standard
identified 195 likely calcifications (14 under 100 HU) and 133 hemorrhages. Both SECT and
DECT were able to identify known calcifications with 100% accuracy. QSM classified two
definitive calcifications incorrectly; one was located near a vein which masked the calcification,
and the other was surrounded by likely hemorrhage. Below a SECT threshold of 100 HU, QSM
was 100% accurate compared to a clinically-derived reference standard. While DECT (and
SECT with an optimized differentiation threshold) narrowly remained the most accurate
modality for identifying hemorrhage and calcification in this dataset, it must be qualified by the
fact that our dataset did not include any hemorrhage with an attenuation between 53 HU and
100 HU on SECT, and no overlap in HU between the hemorrhagic and calcific lesions was
present.

6.2

Advances in Knowledge

This work provided several advances in knowledge and utilized a unique study design which
examined two imaging modalities to arrive at a consensus on the diagnosis of hemorrhage and
calcification. The first advance was the creation of an MR phantom with calcific and
hemorrhagic lesions available for direct comparison with phase-sensitive MRI post-processing
algorithms. Overall, there are very few phantoms described in the MR literature that specifically
included calcium as a material of interest (208, 215, 247). Valdés Hernández et al. did directly
compare iron and calcium in a phantom using calcium carbonate and superparamagnetic iron
oxide nanoparticles in alginate beads, which is a gel similar to agarose (215). They utilized the
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phantom to differentiate between calcification and hemorrhage models using only T1-weighted
and T2-weighted magnitude image features. However, their lesion models were approximately
1-3 mm in diameter, which would not have provided an adequate volume for quantitative
measurements within the lesion models (215). More importantly, they were unable to control
the exact concentration of their gels. Utilizing phase-based image processing such as QSM
allows us to interrogate the imaging data for a quantity that directly correlates with the
concentration of these material types as well as providing thresholds for the accurate
differentiation of calcification and hemorrhage.

We also validated several materials that could potentially simulate hemorrhage on MRI. There
are several quantities of interest that we would ideally like to match in order to simulate these
lesions adequately in phantoms. The first, which we investigated extensively, was the T2* value
associated with various concentrations of materials. This quantity defines the exponential
decay of the signal in a multi-echo T2*-weighted GRE sequence as the echo time (TE)
increases. This has been extensively reported in the literature for many tissue types (209-212).
The second quantity of interest is the magnetic susceptibility, which should increase gradually
with increasing iron content to mimic most iron-laden tissues. We validated that our materials,
particularly iron dextran, behaved very similarly to human hemoglobin (primarily in the form of
methemoglobin). While most studies utilize superparamagnetic iron oxide nanoparticles
(SPIOs) in phantoms, they are very expensive relative to iron dextran (which can be acquired
through most chemical suppliers), and the ratio of susceptibility to iron concentration is
incredibly high, outside of the biologically-expected range, due to the superparamagnetic
properties of the nanoparticles (see Section 2.4.3). Therefore, very small differences in SPIO
concentration could cause a very large shift in the susceptibility, and errors in the physical
measurement of the compound would have an unduly large impact on the phantom data.
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The design of our patient study is also unique, and—to our knowledge—we are the first group
to attempt an investigation of intracranial lesions specifically under 100 HU. While DECT and
QSM have been used to differentiate between calcification and hemorrhage in vivo in individual
retrospective studies (137, 205, 206), there have been no studies attempting to compare the
two modalities directly and prospectively. Because we acquired non-contrast SECT in the same
session as non-contrast DECT and phase-sensitive MRI, we could compare the conventional
methods of identifying calcification to that of more recent image processing methodologies. We
included naturally occurring calcifications in our analysis. This allowed us to analyze calcific
lesions within nearly every patient, and the degree of calcification in these normal tissues (i.e.,
the pineal gland and choroid plexus) returned highly varied attenuation levels, definitively
demonstrating the presence of calcification under the 100 HU SECT threshold currently used
clinically.

Along with other studies in the literature, we have been able to help establish the range of
susceptibility values expected within chronic hemorrhagic lesions. This is important moving
forward so that pulse sequences that will be used for QSM processing can be optimized to
work for a wide variety of patients. While we did not optimize our pulse sequence for
visualization of the vasculature, we were able to easily visualize and identify hemorrhagic
metastases as well as calcific lesions under 100 HU on SECT.

6.3

Limitations

There are several major limitations to the methodologies employed in this study. The first is that
the samples in the phantom were cylindrical, and therefore resulted in orientation dependence
on the susceptibility-weighted MRI sequences. It would be advantageous to develop spherical
molds of various sizes to eliminate this orientation dependence; it would also allow for the vials
themselves to be eliminated from the phantom design. While the vials did not cause artifacts
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within the QSM images, removing them would minimize the number of abrupt boundaries in the
susceptibility map and may better represent the shape of most lesions within the brain.

One of the main limitations to potential clinical translation discovered during this work is the
time required for QSM processing of large datasets. A patient dataset took approximately six
hours to reconstruct. However, this reconstruction was performed on a server with eight 2.8
GHz Dual-Core Opteron 8220 (Advanced Micro Devices, Santa Clara, CA) processors, which
were released in 2007. Given modern processing speeds, reconstruction times should be
approximately 1 hour, provided sufficient RAM is available on the system. While this process
was performed offline for this study, the MEDI algorithm has been licensed to MR
manufacturers and may become commercially available in the near future.

Finally, the patient population enrolled in the clinical trial was heavily weighted towards patients
with chronic hemorrhage, as discussed extensively in Section 5.4. While this represents the
majority of the outpatients with hemorrhagic lesions at our oncology-focused institution, it is not
representative of what may be seen in an emergent or inpatient setting, particularly at hospitals
that are more likely to treat hemorrhagic stroke or traumatic brain injury. Including patients with
acute hemorrhage in the study would allow us to study the true differentiation of hemorrhage
and calcification with SECT attenuation levels between 60 and 100 HU in a more
representative patient population. However, it would be difficult to acquire all of the imaging for
this study in one imaging session. Given the potential for temporal evolution of acute
hemorrhage and/or surgical intervention, the temporal matching of the CT and MRI exams
would be of even greater importance and be much more difficult to achieve without
compromising care for these patients.
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6.4

Future Work

There are multiple avenues for research to be pursued using this dataset—both phantom and
human—as an extension of this work. The phantom data provides a reference for many
different iron-based materials that are similar to materials found within the body. By utilizing
phantoms akin to those created throughout the course of this work, we can further investigate
image quality concerns that may arise during QSM processing, such as phase aliasing. By
replicating these image quality issues in phantoms, we can test additional algorithms to detect
and correct for potential errors. The phantoms may also be used as a reference to begin iron
quantification studies using QSM and DECT. We can use the phantom data that has already
been acquired, along with the patient data, to assess the accuracy of QSM when performed
with fewer echoes or other pulse sequences, such as the ultrashort echo time sequence
acquired alongside the other susceptibility-weighted sequences (248).

Within the patient dataset, one research area in which our dataset is particularly suited is in
comparing image quality and quantitative metrics between SECT and DECT in both normal
tissue and lesions. There are no existing guidelines for translating diagnostic thresholds from
years of experience with SECT to the new paradigm of DECT. While some vendors provide a
mixed image which may be a reasonably close match to a conventional 120 kVp SECT, other
vendors may recommend using monoenergetic images as a replacement for SECT. Therefore,
it is paramount that we are able to either find monoenergetic energies for which various tissue
compartments have mean CT numbers equal to the 120 kVp SECT Hounsfield Unit, or that we
find an algorithm that can convert a SECT threshold to its monoenergetic equivalent.

We acquired several pulse sequences as a part of the clinical trial that were not explicitly
described in this dissertation. Several may be utilized in other studies for differentiation of
calcification and hemorrhage. We acquired an Ultrashort Echo Time (UTE) sequence which
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can provide signal even within the bony anatomy, and may assist in the identification of dense
calcification which has a very low proton density and, consequently, a low signal on
conventional MRI sequences. We also have acquired a synthetic MR sequence which can be
processed into T1-weighted, T2-weighted, and Proton Density-weighted image series as well
as quantitative maps of T1 and T2. We plan on investigating how results from these two
sequences correlate with the data acquired with QSM.

Ultimately, we would like to see both DECT and QSM adopted for appropriate brain imaging in
the clinic. We have extensively studied quantitative differentiation of calcific and hemorrhagic
lesions on a fast kVp switching DECT system, but to adapt this protocol to other systems, it
would be useful to repeat some of the imaging performed by Nute et al. to optimize the
workflow (136). Using images from our current study, we could also perform a reader study to
determine if chronic hemorrhagic lesions can be visualized on DECT without registration to an
MR image. Following these steps, implementing DECT for routine brain scans either in the
inpatient or outpatient settings would require that we reduce the CTDI vol (currently 132.6 mGy).
To counteract the increase in noise caused by lowering the dose, we would also increase the
image thickness to 3.75 mm in an attempt to maintain reasonable signal-to-noise ratios. Finally,
we would need to develop the workflow so that all required DECT images (calcium, water,
SECT equivalent) would be reconstructed automatically and sent to PACS for radiologists’
viewing.

Implementing QSM in a clinical environment may be more technologically challenging than
introducing DECT. First, the MFGRE sequence we used had an acquisition time near 7
minutes in patients. This would need to be shortened for clinical acceptance, and so we would
likely need to decrease the number of echoes acquired and potentially adjust the spatial
resolution. Trained staff would be required to initiate QSM processing, which requires
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significant computational power to complete in a reasonable amount of time. This may become
easier as several vendors, including General Electric, have licensed the MEDI QSM software
for implementation on their workstations. However, lesions close to the bone-tissue boundary
may be left out of the automated selection of brain tissue, and the images would need to
undergo careful quality assurance before being available for radiologists to read.

In summary, our major findings were that DECT and QSM improved on the current clinical
SECT threshold of 100 HU for differentiating between hemorrhagic and calcific lesions in a
prospective clinical trial. In the future, we would like to pursue an additional clinical trial of
patients with acute hemorrhage in an emergent setting.
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Appendix 1

Contraindications to MR Imaging
Subjects and employees must report the presence of the following devices or conditions because
they may be contraindications to MR, as reported in Appendix II of the American College of
Radiology Guidance Document on MR Safe Practices (249):


















Heart pacemaker or defibrillator
Neuro- or bio-stimulator
Cochlear implants
Cerebral aneurysm clips
Intravascular coils/filter/stents
Any metal in the eyes
Any ocular implant
Artificial heart valve
Surgical clips or staples
Implanted drug pump
Joint replacements
Limb prosthesis
Body piercing
Hearing aids
Internal electrodes/wires
Implants held by magnets
















Bullet fragments/shrapnel
Existing catheters/ports
Eyelid spring
Tissue expander
Penile implant
Intrauterine contraceptive device
Rods/screws/plates
Any other implanted device
Medication patch
Tattoos
Halo vest
Spinal fixation device or spinal fusion
procedure
Surgical mesh
Brachytherapy radioactive seeds

Additionally, all metallic objects must be removed from the subject’s person before their
entering the MRI suite. Items specifically indicated by the American College of Radiology
(249) include, but are not limited to:


















Hearing aids
Pagers
Cell phones
Keys
Hair pins/Barrettes
Watches
Safety pins
Paper clips
Metallic money clips
Credit cards or any card with a
magnetic strip
Coins
Pens
Pocket knives
Nail clippers
Steel-toed shoes
Tools
Dentures or false teeth






Eyeglasses
Clothing with metal fasteners or
zippers
Jewelry, including body piercings
Any other loose, metallic items
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8 Appendix 2
Clinical Trial Screening Procedure and Software

Figure 8.1: Clinical trial screening software example.
The screening software, developed using a combination of Python, Javascript, and Standard
Query Language (SQL), was a web-based application that pulled all T2*-weighted GRE MRI of
the head from the Picture Archiving and Communication System (PACS). The daily screening
was performed in which study personnel cycled through all of the series for a given day to
identify foci of susceptibility with at least one axis longer than 1.0 cm, such as the two lesions
shown in the patient image in Figure 8.1. The numeric references in the figure above represent
the following:
1. Patient Image
Patient datasets are displayed in Area 1 (Figure 1). The white box in the upper left-hand
corner of the image represents an area of 1cm x 1cm for reference. Users may scroll
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through images by hovering the mouse over this image and using the up/down arrow
keys or the scroll wheel on the mouse.
2. Patient Information
Relevant patient information is displayed in Area 2 (Figure 1). These include the MRN,
Patient Name, Dataset number (out of total acquired that day), Series Description, and
Image Number within the series.
3. Image Selection and Commenting
Images of interest may be “marked” for later review by clicking the “Mark Image” button
in Area 3 (Figure 1). A comment may be entered before imaging marking by entering
text into the empty box left of the “Mark Image” button. Patients may be selected as
potential study recruits by clicking “Recruit Patient.”
4. Cycle Button and Cycle Speed
Users may cycle through the patient series by clicking “Cycle” (Area 4, Figure 1). Cycle
speed may be adjusted in the box to the left. Alternatively, users may hover the mouse
over the patient image and press “CTRL” on the keyboard to start and stop cycling.
5. Marked Image Table
Marked images appear along with patient information in Area 5 (Figure 2) along with any
user comments and the MDA Username of the user that marked the image.
6. Potential Recruit Table
Patients that are eligible to be recruited to the study will be collected in Area 6 (Figure 2).
7. Patient Image Buttons
Clicking on these images (Area 7, Figure 2), will automatically open the image in the
main image viewer.
8. Open Study Button
Opens a dialog box that allows the user to open a specific patient image series (Area 8,
Figure 2).
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9. Copy MRN Button
Automatically copies the patient MRN for entry into Epic or iSite. A dialog box will appear
to confirm that the data was copied successfully.
10. Date Selection
Clicking on the date (Area 10, Figure 2) brings up a calendar that allows the user to look
at prior screening days. Click submit to go to images from that date.
11. Table Controls
The buttons located in Area 11 (Figure 2) control various table functions. “Refresh”
reloads the tables. “Open Table In New Window” opens both tables in a full screen view
with the recruiting table at the top. “Prelim Screening Complete” sends an e-mail to Dr.
Schellingerhout noting that screening has been completed and is ready for review.
“Send All Recruiting Emails” sends an e-mail to study staff, including the research
nurses, containing the recruiting table and links to individual patient data pages.
Lesions were marked when they were greater than 1.0 cm in length unless they represented
one of the following known imaging artifacts or lesion types:
1.

Sinuses

Figure 8.2: Dark lesion appearing in the right hemisphere (left, arrow). The next image in
the series (middle) shows that both sides are symmetric. An example of the sagittal
anatomy on T1-weighted imaging (https://www.imaios.com/en/e-Anatomy/Head-andNeck/Brain-MRI-3D) with the level of the "lesions" shown
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2. Dura Mater Calcifications

Figure 8.3: A calcification in the dura mater inside the skull (A) and separating the cerebral
hemispheres (falx cerebri, B). These known calcifications can appear as dark lines along
part or all of the falx cerebri.
3. Basal Ganglia Mineralization

Figure 8.4: Iron deposition in the putamen (left, arrows) and globus pallidus (right, arrows)
in the basal ganglia.

132

4. Pineal Gland Calcification

Figure 8.5: Pineal gland calcification located centrally in the image.
5. Choroid Plexus Calcifications

Figure 8.6: Choroid Plexus (arrows) mineralization. Usually found on the same slice or near
the z-location of the pineal gland.
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6. Dentate Nuclei

Figure 8.7: Iron deposition found in the Dentate Nuclei (arrows) in the cerebellum. This can
appear darker, similar to the basal ganglia examples.
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